Methods for mid-to-bottom antibody characterization
Antibodies are cleaved by cathepsin L and/or cathepsin D to generate fragments suitable for conventional MS instruments. Combined with mass spectrometry analysis, this method solves the problems of limited antibody sequencing coverage and splicing difficulties in existing technologies, and achieves efficient and accurate antibody sequence identification.
Patent Information
- Application Number
- CN202180060336.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2020-07-20
- Filing Date
- 2021-07-19
- Publication Date
- 2026-11-17
- Estimated Expiration
- 2041-07-19
AI Technical Summary
Existing antibody sequencing methods, when using conventional MS instruments, struggle to completely lyse long antibody fragments, resulting in limited coverage of de novo sequencing. Furthermore, bottom-up analysis software assembly presents significant challenges, making it difficult to accurately determine antibody sequences.
Antibodies were cleaved using cathepsin L and/or cathepsin D to generate protein fragments suitable for commonly used LC-MS/MS CID and HCD instruments. Combined with mass spectrometry analysis, VL, VH, CL and CH fragments were separated and identified, and antibody sequence identification was performed using a middle-to-bottom method.
It improves the accuracy and efficiency of antibody sequencing, is compatible with conventional MS instruments, simplifies the sequence assembly process, and enhances the analytical capabilities of antibody fragments.
Smart Images

Figure CN116324416B_ABST
Abstract
Description
[0001] Cross-citation of related applications
[0002] This application claims priority to U.S. Provisional Application No. 63 / 053899, filed July 20, 2020, the contents of which are incorporated herein by reference in their entirety. Technical Field
[0003] This disclosure relates to novel methods for antibody characterization and sequencing, such as mid-to-bottom antibody characterization and sequencing, for example, for de novo antibody sequencing, identification of known antibodies in a sample, or verification of antibody sequences in a sample. In some embodiments, these methods involve exposing the antibody to cathepsin D, cathepsin L, and / or cathepsin D and L, followed by mass spectrometry and sequence identification and deconvolution. Background Technology
[0004] Current methods for identifying protein sequences (such as antibody sequences) in samples include bottom-up, mid-down, and top-down analysis. In bottom-up analysis, which is used in the vast majority of cases, several different proteases (e.g., 4-5 proteases) are typically used to produce relatively short overlapping peptides (e.g., 9-30 amino acids long or about 1-5 kDa) for liquid chromatography (LC) and mass spectrometry (MS) analysis. For example, if such a protocol is performed to determine the sequence of an unknown antibody (i.e., de novo sequencing), a large number of mass spectra must be generated and subsequently assembled using specialized sequencing programs that use information about the mass shift extracted between product ion peaks. One limitation of this method is that the accuracy of sequence analysis can depend on obtaining extremely high-quality MS data (e.g., tandem MS (MS / MS) cleavage efficiency and low mass error) and detecting peptides spanning the entire protein. Furthermore, bottom-up analysis can pose software challenges because it may require correctly splicing together the sequence information of a large number of small peptides into a complete protein sequence. Mid-down methods using a small number of peptides or protein fragments may help alleviate these software challenges.
[0005] A top-down approach can be used for antibodies, where, for example, the antibody is first cleaved near or within the hinge region between the CH1 and CH2 regions of the heavy chain to produce, for example, F(ab')2, F(ab'), Fc, Fd, and VL-CL fragments. The most commonly used enzyme is the cysteine protease IdeS from *Streptococcus pyogenes*, which is cleaved after the hinge region to produce the F(ab')2 and Fc / 2 fragments. Following disulfide bond reduction, light chain (LC) fragments, Fd' fragments, and Fc fragments are produced, each approximately 25 kDa in size and approximately 200 amino acids in length.
[0006] When analyzed using conventional MS instruments, these relatively long fragments are difficult to lyse completely and may therefore be unsuitable for de novo sequencing. For example, commonly used MS instruments include time-of-flight instruments with collision-induced dissociation or Orbitrap. TM High-energy collisional dissociation (HCD) instruments lack both electron-induced dissociation (an efficient orthogonal fragmentation method) and UV dissociation (which is also suitable for very large peptides). Therefore, bottom-up sequencing methods may be needed to supplement the limited coverage of mid-to-bottom methods for de novo antibody sequencing. Thus, alternative mid-to-bottom methods are required that produce protein fragments more suitable for commonly used, industry-standard LC-MS / MS CID and HCD instruments, and are therefore more practical. Summary of the Invention
[0007] This invention particularly includes a method for cleaving antibodies, comprising mixing an antibody with cathepsin L, cathepsin D, or a combination of cathepsin L and cathepsin D to obtain one or more antibody fragments, wherein the antibody comprises a light chain and a heavy chain, the light chain comprising a light chain variable region (VL) and a light chain constant region (CL), the heavy chain comprising a heavy chain variable region (VH) and a heavy chain constant region (CH), and wherein cathepsin L and / or D cleaves the antibody between the VL and CL regions and / or between the VH and CH regions to produce VL antibody fragments and / or VH antibody fragments and CL antibody fragments and / or CH antibody fragments. In some embodiments, the method further includes separating one or more of the antibody fragments after cleavage. In some embodiments, the antibody fragments are not separated after cleavage. In some embodiments, after cleavage, one or more antibody fragments are analyzed by mass spectrometry.
[0008] For example, the present invention also covers a method for analyzing antibody sequences, comprising: (a) cleaving an antibody with cathepsin L, cathepsin D, or a combination of cathepsin L and cathepsin D to obtain one or more antibody fragments, wherein the antibody comprises a light chain and a heavy chain, the light chain comprising a light chain variable region (VL) and a light chain constant region (CL), the heavy chain comprising a heavy chain variable region (VH) and a heavy chain constant region (CH), and wherein cathepsin L and / or D cleaves the antibody between the VL and CL regions and / or between the VH and CH regions to produce VL antibody fragments and / or VH antibody fragments and CL antibody fragments and / or CH antibody fragments; (b) optionally separating one or more of the antibody fragments after cleavage; and (c) performing mass spectrometry (MS) analysis on the one or more antibody fragments.
[0009] In any of the above methods, in some embodiments, the antibody is an IgG antibody, such as human IgG1, IgG2, IgG2A, IgG2B, or IgG4 antibody. In some embodiments, cleavage produces VL and / or VH fragments. In some such embodiments, the VL and / or VH fragments are subjected to MS analysis. In some methods herein, the heavy chain constant region comprises at least a CH1 region and optionally further comprises a hinge, a CH2 region, and / or a CH3 region. In some methods herein, the antibody heavy chain constant region comprises at least a CH1, a hinge, and a CH2 region, and wherein cathepsin L and / or cathepsin D further cleave the antibody between the CH1 region and the hinge.
[0010] In some embodiments, the antibody is cleaved with cathepsin L. In some embodiments, the antibody is cleaved with cathepsin D. In some embodiments, the antibody is cleaved with a combination of cathepsin L and cathepsin D. In some cases, an additional enzyme, such as IdeS or another protease, is also used. In other cases, the enzyme used for cleavage consists of cathepsin L, cathepsin D, or a combination of cathepsin L and cathepsin D. In some cases, the method includes simultaneously incubating the antibody with cathepsin L and cathepsin D.
[0011] In some embodiments, cleavage is performed to achieve at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or 100% cleavage between the VL and CL regions and between the VH and CH regions. In some cases, cleavage is performed to achieve at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or 100% cleavage at or below the hinge. In some cases, the antibody is an IgG antibody and is cleaved by a combination of cathepsin L and cathepsin D, wherein the cleavage yields VL, VH, CL, CH1, CH2, CH3, CH2-CH3, CL+CH1 (bonded), F(ab'), and F(ab')2 fragments. In some embodiments, cleaving produces fragments containing each of the light chains CDR1, CDR2, and CDR3, such as VL, F(ab'), or F(ab')2 fragments, and / or fragments containing each of the heavy chains CDR1, CDR2, and CDR3, such as VH, F(ab'), or F(ab')2 fragments.
[0012] In some of the methods described herein, cleavage is performed by incubating the antibody with cathepsin L, cathepsin D, or a combination of cathepsin D and L at pH 2–8 (such as pH 2–7, pH 2–6, pH 3–6, pH 3–5, pH 2, pH 2.5, pH 3, pH 3.5, pH 4, pH 4.5, pH 5, pH 5.5, pH 6, pH 7, or pH 8) at temperatures from room temperature to 50°C, and in the presence of no more than 50% organic solvent (e.g., acetonitrile, methanol, ethanol, or isopropanol), wherein the antibody is in its native state. In some methods described herein, the cleavage is performed in the presence of one or more organic solvents (e.g., methanol, ethanol, isopropanol, or acetonitrile) at concentrations of 0-50%, 5-50%, 5-30%, 0%-30%, 10-30%, 0-10%, 5-15%, 10-20%, 15-25%, or 20-30%. In some methods described herein, including those involving one or more organic solvents (e.g., methanol, ethanol, isopropanol, or acetonitrile) at concentrations of 0-50%, 5-50%, 5-30%, 0-30%, 10%-30%, 0-10%, 5-15%, 10-20%, 15-25%, or 20-30%), the pH is 3-5, such as 3, 3.5, 4, 4.5, or 5. In some such cases, the pH is 3.5 to 4.5. In some such cases, the pH is 4. In some cleavage reactions, the presence of organic solvent does not exceed 30%. In some such cases, cleavage is carried out in the presence of 10-30% organic solvent (e.g., 10-30% acetonitrile, 10-30% methanol, 10-30% ethanol, or 10-30% isopropanol). In some cleavage reactions, the presence of organic solvent does not exceed 10%. In some cleavage reactions, the temperature is between 37°C and 50°C.
[0013] The disclosure herein also includes methods for analyzing antibody sequences, comprising: (a) using an antibody with a combination of cathepsin L and cathepsin D to obtain one or more antibody fragments comprising at least one light chain variable region (VL) fragment and / or heavy chain variable region (VH) fragment; (i) wherein the antibody is in a native state; (ii) wherein the antibody contains a light chain comprising a light chain variable region (VL) and a light chain constant region (CL), and a heavy chain comprising a heavy chain variable region (VH) and a heavy chain constant region (CH), and wherein cathepsin L and D cleave the antibody between the VL and CL regions and / or between the VH and CH regions to produce VL antibody fragments and / or VH antibody fragments and CL antibody fragments and / or CH antibody fragments; and (iii) wherein the cleavage is performed at a temperature between 25°C and 50°C and a pH between 3 and 5, and in the presence of no more than 30% organic solvent; (b) optionally separating one or more of the antibody fragments after cleavage; and (c) performing mass spectrometry (MS) analysis on one or more antibody fragments.
[0014] In any of the methods described herein, after cleavage, one or more antibody fragments may be subjected to one or more of the following: buffer exchange, chromatography (e.g., liquid chromatography, such as high-performance liquid chromatography, or capillary electrophoresis), filtration (e.g., molecular weight cutoff filtration), disulfide bond reduction, contact guanidine hydrochloride, or alkylation. For example, one or more of these steps may be performed prior to MS analysis or on a portion of the sample to be analyzed (e.g., reduction or alkylation of a portion of the sample to compare MS partitions with and without these alterations). In some embodiments, one or more antibody fragments after cleavage are separated by chromatography or filtration. In some such cases, one or more antibody fragments are separated by liquid chromatography.
[0015] In some embodiments where MS analysis is performed, the MS includes LC-MS or LC-MS / MS. In other embodiments, the one or more antibody fragments are not separated after cleavage. In some embodiments where mass spectrometry is performed, the mass spectrometry includes direct injection mass spectrometry (DIMS), static spray infusion mass spectrometry, or flow injection mass spectrometry.
[0016] In some embodiments of the present invention that perform mass spectrometry, the mass spectrometry data is used to determine the amino acid sequence of at least 10 amino acid extensions of an antibody fragment. In some embodiments, the amino acid sequence of at least 15 amino acid extensions of an antibody fragment is determined. In some embodiments, the amino acid sequence of at least 20 amino acid extensions of an antibody fragment is determined. In some embodiments, the amino acid sequence of at least one antibody CDR region is determined. In some embodiments, the sequences of CDR1, CDR2, and CDR3 of VH and / or VL are determined. In some embodiments, the complete amino acid sequence of at least one antibody fragment, such as a VH fragment and / or a VL fragment, is determined. In some embodiments, the sequence is determined by top-down analysis. In some embodiments, the sequence is further analyzed or confirmed by bottom-up analysis. In some embodiments, the amino acid sequence of the antibody VH region and / or VL region is unknown. In some embodiments, the amino acid sequence of the antibody is unknown. Some embodiments also include MS analysis of the CL and / or CH regions of the antibody, such as CL, CH1, CH2, and / or CH3 fragments resulting from cleavage. In some cases, any method herein further includes Edman degradation of at least one antibody fragment. In some methods described herein, cleavage is performed at the following ratios of cathepsin L and / or cathepsin D to antibody: 1:20 to 1:2000, 1:20 to 1:500, 1:50 to 1:500, 1:100 to 1:500, 1:200 to 1:1000, 1:200 to 1:2000, 1:500 to 1:2000, 1:1000 to 1:2000, or 1:20, 1:50, 1:100, 1:200, 1:300, 1:400, 1:500, or 1:1000. In some methods described herein, the antibody remains in its native state after cleavage. In some methods described herein, the antibody is not treated with denaturing agents or disulfide-reducing agents during or after cleavage. In some methods described herein, the antibody retains its disulfide bonds during and after cleavage. Some of the methods described in this article involve mass spectrometry (MS) analysis of one or more antibody fragments after cleavage, wherein the antibodies remain in their native state and have not been treated with denaturing agents or disulfide-reducing reagents prior to MS analysis.
[0017] The present invention also includes compositions comprising antibody fragments generated according to the methods described above. In some cases, the composition comprises an IgG antibody fragment generated using cathepsin L, cathepsin D, or a combination of cathepsin L and D, wherein the antibody fragment comprises one or both of a VH fragment and a VL fragment, and at least one, at least two, or at least three of the following fragments: CL, CH1, CH2, CH3, CH2-CH3, CL+CH1 (bonded), F(ab'), and F(ab')2. In some cases, the length of the VH and / or VL fragment comprises 90 to 150 amino acids, such as 95 to 140 amino acids, such as 100 to 140 amino acids, or such as 100 to 120 amino acids. In some such cases, the VH and / or VL fragment has a molecular weight of 10-16 kDa, such as 10-13 kDa, such as 10-12 kDa, such as 10-11 kDa, or such as 11-12 kDa.
[0018] The present invention also includes a kit for digesting proteins with cathepsin L, cathepsin D, or a combination of cathepsin L and cathepsin D, the kit comprising (a) cathepsin L and / or cathepsin D; (b) one or more reaction buffers; and optionally (c) instructions regarding protein digestion. In some cases, the kit provides reagents for cleaving antibodies according to the methods described above. In some kits, the reaction buffer is pH 2-8, pH 2-7, pH 2-6, pH 2-5, pH 3-6, pH 3-5, pH 3-4, pH 4-5, pH 2, pH 2.5, pH 3, pH 3.5, pH 4, pH 4.5, pH 5, pH 5.5, pH 6, pH 7, or pH 8; and the reaction buffer contains one or more organic solvents. In some embodiments, the reaction buffer contains one or more organic solvents (e.g., methanol, ethanol, isopropanol, or acetonitrile) at concentrations of 0-50%, 5-50%, 5-30%, 0-30%, 10%-30%, 0-10%, 5-15%, 10-20%, 15-25%, or 20-30%. In some cases, the pH of the reaction buffer is 3, 3.5, 4, 4.5, or 5. In some kits, the pH of the reaction buffer is 4.
[0019] It should be understood that the foregoing general description and the following detailed description are exemplary and illustrative only, and do not limit the scope of the claims. The accompanying drawings, which are incorporated in and form a part of this specification, illustrate certain embodiments or aspects and, together with the specification, serve to explain the principles described herein. Attached Figure Description
[0020] Figure 1A -D shows the spectrum of rituximab exposed to cathepsin L. Figure 1A -B shows the full-spectrum rituximab exposed to cathepsin L, showing approximately 10 kDa of CDR L3 cleavage, approximately 47 kDa of “single-arm” cleavage, approximately 100 kDa of complement from the single-arm cleavage (e.g., 100,238 is the intact monoclonal antibody (mAb), with G1F / G1F at 147,400, 47,178 missing, and water at 18), and approximately 147 kDa of intact mAb. Figure 1C -D shows the charge unconvolution of the same rituximab exposed to the cathepsin L spectrum, focusing on the m / z range (3000-4000) and m range (45000-49000) of the one-arm clip.
[0021] Figure 2A -D shows the spectrum of rituximab exposed to cathepsin D. Figure 2A -B demonstrates single-arm shearing. Figure 2C -D indicates F(ab')2 shearing.
[0022] Figure 3A -D shows the spectrum of obinutuzumab exposed to cathepsin L. Figure 3A -B shows the complete mAb peak. 148630.4 Da matches well with mAbs having G0 / G0 glycosylation, 148834.1 Da matches with additional GlcNAc, and 149038.0 Da matches with two additional GlcNAc. Obinutuzumab is glycoengineered to have a predominantly unfucosylated glycan. Figure 3C -D indicates a single-arm shearing.
[0023] Figure 4A -H shows the spectrum of ozono-eutuzumab exposed to cathepsin D. Figure 4A -B indicates the full spectrum. Figure 4C -D indicates the complete mAb peak. 148628.3 Da matches well with mAbs with G0 / G0 glycosylation, 148,832.9 Da matches with additional GlcNAc, and 149034.7 Da matches with two additional GlcNAc. Figure 4E -F indicates a complete single-arm shear. Figure 4G -H indicates F(ab')2 shearing.
[0024] Figure 5A -D shows the spectrum of eculizumab exposed to cathepsin L. Figure 5A -B indicates the full spectrum. Figure 5C -D indicates CDR H3 shearing.
[0025] Figure 6A-D shows the spectrum of eculizumab exposed to cathepsin D. Figure 6A -B indicates the full spectrum. Figure 6C -DB indicates F(ab')2 shearing.
[0026] Figure 7A -B shows the native mass spectrum of rituximab digested with cathepsin D. Figure 7A The unconvolution across the full m / z range yields peptides of 9–98 kDa, and a large number of intact Abs (approximately 147 kDa) are shown. The peak at 97,684 is generated by truncation below the hinge at LLGGPSVF.L. Asymmetric shearing, such as that at 97,538 formed by F(ab')LLGGPSVF.L + F(ab')LLGGPSV.F, is also observed and is shown in the inset. Figure 7B The unconvolution of the 47kDa region is shown, revealing the diversity of shearing observed at a specific site location F(ab') (which is shown on the IgG1 crystal structure (PDB1HZH)).
[0027] Figure 8 The preferred cleavage sites of cathepsins L (gray lines) and D (plain black lines), alone and in combination, are shown on human IgG1, IgG2-B, and IgG1 antibodies. For the IgG1 class, cathepsins L and D each produce cleavage at CDR3 of the heavy chain (HC) and light chain (LC), above the hinge (F(ab')), and throughout the heavy chain hinge region (gray and black dashed lines). Cathepsin D alone uniquely cleaves the sequence PSVFL.F to produce F(ab')2 (solid black line). The combination of cathepsins L and D produces further cleavage at the locations indicated by black lines with diamonds at each end. Due to the different disulfide bond pattern of eculizumab (IgG2-B), no cleavage was observed in eculizumab within the hinge. In the IgG1 bispecific antibody, no cleavage was observed in the Fc anti-CD3 arm (well) compared to cleavage observed in the anti-Her2 (protrusion) arm.
[0028] Figure 9A -B shows a comparison of the digestive efficiency of cathepsins L and D in different treatments. Figure 9A All identified peptides are shown, as reported in Tables 3 and 11. The peptides were summed and their strength against intact trastuzumab was determined. Figure 9B The UV peak areas of all peptide peaks (corresponding to EIC elution times) are shown in the form of a ratio to the main Ab peak. Error bars represent the standard deviation of the measurement.
[0029] Figure 10A-E illustrates an example of UV and TIC measurements of a pot of cathepsin L and D digests. The insets show the average MS spectra of the selected samples within their elution time windows, deconvoluted in whole mass (protein indices). The masses in these figures may differ slightly from those given in the tables disclosed herein, as the exact mass depends on time, mass, and m / z range, as well as other parameters used in charge deconvolution.
[0030] Figure 11A -D shows the spectrum of a statically injected cathepsin pH 4 sample. Spectroscopy was performed on an ultra-high mass range (UHMR) mass spectrometer using Biorad. The column replaced the sample buffer with 50 mM ammonium acetate. MS1 spectra were obtained at 17,500 resolution at 200 m / z, and charge states were confirmed at 50 K or 100 K resolution in SIM mode. Figure 11A The Rf setting has been adjusted and optimized for high quality (>4000m / z). Figure 11B The Rf setting has been adjusted and optimized for medium quality (1500-4000 m / z). Figure 11C and Figure 11D High-resolution mass spectra of the 12.1 kDa and 47 kDa substances are shown, respectively.
[0031] Figure 12 The Edman degradation partitioning of the optimized digests of cathepsin L and cathepsin D is shown. Amino acids in parentheses “()” are less reliable than those identified as having good reliability.
[0032] Figure 13A -C shows the MS2 spectrum of the selected cathepsin digestion product. Figure 13A The mass spectrum of the 12.1 kDa substance is shown. Figure 13B The mass spectrum of the 47 kDa substance is shown. Figure 13C The mass spectrum of a 98 kDa substance is shown.
[0033] Figure 14A -B indicates a top-down annotation for the selected polypeptide. (This indicates...) Figure 14A )12,121.5Da and ( Figure 14B Coverage of the 98 kDa product, where light gray y ions correspond to HC sequences ending in G, dark gray to GG, and triangles to y-ions with unspecified covalent crosslinking modifications. Black represents HC b ions or LC b / y ions. Spectra were collected via nESI injection, deconvolved using the Xtract algorithm, and matched in ProSight Lite with fragments having a 10 ppm tolerance and using an internal program.
[0034] Figure 15A -C indicates an amino acid enrichment motif. Figure 15A The image shows cathepsin L. Figure 15B The image shows cathepsin D. Figure 15C A pot of cathepsin L and cathepsin D digests is shown. The amino acid preference of p4=p4' was evaluated in Seq2Logo 2.0
[71] .
[0035] Figure 16 Molecular models of trastuzumab and cleavage sites observed after optimizing the digestion protocol are shown. Trastuzumab (PDB 6BI2) LC is shown on the right / top side (looking down), and HC AA 1-221 is shown on the left / top side (looking down). The HC CH2 and CH3 regions are shown in black and combined, showing a single Ab arm (half of an antibody). Trastuzumab F(Ab') was aligned to residues 1-214 of the full-length IgG1 crystal structure (PDB 1HZH) using the internal program GYST and modeled in PyMol 2.3.5. The CH1, CH2, and hinge regions of the aligned IgG1 (AA 228–478) showed 90.9% identity with trastuzumab, with all cleavage sites falling on regions of the same homology. Disulfide bonds were not shown, and Fc glycans were shown as white stripes. Any cleavage sites were shown as spherical models and displayed in black. Detailed Implementation
[0036] definition
[0037] Unless otherwise defined, scientific and technical terms used in conjunction with this invention shall have the meanings commonly understood by one of ordinary skill in the art.
[0038] In this application, unless otherwise stated, the use of “or” means “and / or”. In the context of multiple dependent claims, the use of “or” refers only to one or more prior independent or dependent claims in the alternatives. Similarly, terms such as “element” or “part” cover elements and parts comprising a single unit as well as elements and parts comprising more than one subunit, unless otherwise specified.
[0039] As used herein, any concentration range, percentage range, ratio range, or integer range shall be understood to include any integer value within the range, and, where appropriate, its fractions (e.g., one-tenth and one-hundredth of an integer), unless otherwise stated.
[0040] Units, prefixes, and symbols are represented in their forms accepted by the Système International de Unites (SI). Numerical ranges include the numbers defining the range. The headings provided herein are not intended to limit the various aspects of this disclosure, all of which can be obtained by referencing the entire specification. Accordingly, the terms directly defined below are defined more fully by reference to the entire specification.
[0041] As used in accordance with the invention, unless otherwise indicated, the following terms shall be understood to have the following meanings:
[0042] As used in this article, "sample" means any sample that may contain the protein or antibody that needs to be analyzed.
[0043] The terms "peptide" and "protein" are used interchangeably and refer to polymers of amino acid residues. Such polymers of amino acid residues may contain natural and / or non-natural amino acid residues, and include, but are not limited to, peptides, oligopeptides, dimers, trimers, and polymers of amino acid residues. The term also includes polymers of amino acids that have modifications such as glycosylation, sialylation, or are complexed with other molecules.
[0044] In this article, “peptide” refers to a relatively short polymer of amino acids, such as approximately 4 to 50 amino acids.
[0045] The term “antibody” or “Ab” is used herein in the broadest sense and covers a wide range of antibody structures, including but not limited to monoclonal antibodies (“mAb”), polyclonal antibodies, and multispecific antibodies (e.g., bispecific antibodies), provided they exhibit the desired antigen-binding activity. As used herein, the term refers to a molecule comprising at least complementarity-determining regions (CDRs) 1, CDR2, and CDR3 of a heavy chain and at least CDR1, CDR2, and CDR3 of a light chain, wherein the molecule is capable of binding to an antigen. The term antibody also includes, but is not limited to, chimeric antibodies, humanized antibodies, human antibodies, and antibodies from various species, such as mice, cynomolgus monkeys, etc. The term also covers antigen-binding fragments. The term “antigen-binding fragment” includes, but is not limited to, fragments of an antibody capable of binding an antigen, such as Fv, single-chain Fv (scFv), Fab, Fab', and (Fab')2. In contrast, “full-length antibody” refers to an antibody molecule that includes all of its normal variable and constant regions. Like other proteins and peptides, in some embodiments, antibodies may contain various types of post-translational modifications, such as glycosylation.
[0046] A “fragment” (“antibody fragment”) of a protein, peptide, or antibody generally refers to a portion or region of a larger molecule, such as an Fc or F(ab’)2 fragment of an antibody or peptide obtained by enzymatic cleavage of a protein. For example, protein fragments, such as antibody fragments, can be generated by enzymatic cleavage in the methods described in this invention, or they can be generated during mass spectrometry.
[0047] In this article, "native state" refers to proteins or antibodies that retain their native fold structure and disulfide bonds and have not been denatured, unfolded, or reduced to remove the disulfide bonds. For example, native state proteins can relax their native folds without denaturing or unfolding the protein in the presence of sufficient organic solvents.
[0048] The term "heavy chain" or "HC" refers to a polypeptide containing at least one heavy chain variable region and having or not having a leader sequence. In some embodiments, the heavy chain contains at least a portion of the heavy chain constant region. The term "full-length heavy chain" refers to a polypeptide containing a full-length heavy chain variable region and a full-length heavy chain constant region, having or not having a leader sequence, and having or not having a C-terminal lysine (K). The term "mature full-length heavy chain" refers to a polypeptide containing a heavy chain variable region and a heavy chain constant region, without a leader sequence, and having or not having a C-terminal lysine (K). In some embodiments, the heavy chain contains post-translational modifications, such as pyroglutamic acid modification, while in other cases, the heavy chain does not contain such modifications.
[0049] The term "heavy chain variable region" or "VH" refers to the region containing the heavy chain complementarity-determining region (CDR) 1, backbone region (FR) 2, CDR 2, FR 3, and CDR 3. In some cases, the VH also contains some or all of FR1 before CDR1 and / or some or all of FR4 after CDR3. "Full-length VH" refers to a VH containing complete FR1 and FR4, which are located before and after the CDR1, FR, CDR2, FR3, and CDR3 segments, respectively. As used herein, "before" or "prior to" the second segment refers to the first segment at the N-terminus of the second segment. "After" the second segment is the first segment at the C-terminus of the second segment. In EU designations, the VH of human IgG antibodies typically contains amino acids 1-117 of the heavy chain.
[0050] The term "light chain" or "LC" refers to a polypeptide containing at least one light chain variable region, with or without a leader sequence. In some embodiments, the light chain contains at least a portion of a light chain constant region. The term "full-length light chain" refers to a polypeptide containing both a full-length light chain variable region and a full-length light chain constant region, with or without a leader sequence. The term "mature full-length light chain" refers to a polypeptide containing both a light chain variable region and a light chain constant region, without a leader sequence. In some cases, the light chain may contain post-translational modifications, while in others it may not.
[0051] The term "light chain variable region" or "VL" refers to the region comprising light chain CDR1, FR2, HVR2, FR3, and HVR3. In some embodiments, the light chain variable region also comprises at least a portion of FR1 and / or FR4. "Full-length VL" refers to a VL comprising complete FR1 and complete FR4, which are located before and after the CDR1, FR, CDR2, FR3, and CDR3 segments, respectively. In EU designations, the VL of human antibodies typically comprises 1-107 amino acids from the heavy chain.
[0052] As used herein, the term "heavy chain constant region" or "CH" refers to the region following the heavy chain variable region, containing one, two, or three heavy chain constant regions. H 1. C H 2 and C H 3. And any segments connecting those regions. The constant region of the IgG antibody heavy chain typically has three regions, called CH1, CH2, and CH3, with a short "hinge" region between CH1 and CH2. The CH2 and CH3 regions together form the "Fc" fragment of the antibody. The "hinge" region of IgG antibodies refers to a short amino acid sequence region between the CH1 and CH2 portions of the heavy chain, which is relatively flexible in the native state of the antibody. In EU numbering, the hinge region of human IgG antibodies is found at approximately amino acids 216-230 of the heavy chain, while the CH1 region is at approximately amino acids 118-215, CH2 at approximately amino acids 231-340, and CH3 at approximately amino acids 341-447.
[0053] Non-limiting exemplary heavy chain constant regions include γ, δ, and α. Non-limiting exemplary heavy chain constant regions also include ε and μ. Additionally, antibodies containing the γ constant region are IgG antibodies, antibodies containing the δ constant region are IgD antibodies, and antibodies containing the α constant region are IgA antibodies. Furthermore, antibodies containing the μ constant region are IgM antibodies, and antibodies containing the ε constant region are IgE antibodies. Certain isotypes may be further subdivided into subclasses. For example, IgG antibodies include, but are not limited to, IgG1 (containing the γ1 constant region), IgG2 (containing the γ2 constant region), IgG3 (containing the γ3 constant region), and IgG4 (containing the γ4 constant region) antibodies; IgA antibodies include, but are not limited to, IgA1 (containing the α1 constant region) and IgA2 (containing the α2 constant region) antibodies; and IgM antibodies include, but are not limited to, IgM1 and IgM2.
[0054] In some embodiments, the heavy chain constant region, backbone region, or light chain constant region contains one or more mutations (or substitutions), additions, or deletions that confer the desired characteristics to the antibody. For example, a non-limiting exemplary mutation is found in the human IgG4 hinge region (in the constant domain C). H 1 and C HThe S241P mutation in (between 2 and 3) modifies the IgG4 motif CPSCP to CPCCP, which is similar to the corresponding motif in IgG1. This mutation produces a more stable IgG4 antibody. See, for example, Angal et al., Mol. Immunol. 30:105-108 (1993); Bloom et al., Prot. Sci. 6:407-415 (1997); Schuurman et al., Mol. Immunol. 38:1-8 (2001).
[0055] As used herein, the term "light chain constant region" or "CL" refers to the region following the VL region and may be simply referred to as "CL". Non-limiting exemplary light chain constant regions include λ and K. In EU designations, the CL of human antibodies typically contains amino acids 108-214 of the heavy chain.
[0056] "IgG" or "immunoglobulin G" antibodies are one of several mammalian antibody classes (others include IgA, IgM, etc.) and contain a γ constant region. They are tetrameric proteins formed by two heavy chains and two light chains. The light chains typically contain a variable region and a light chain constant region (VL and CL, respectively). The heavy chains typically contain a heavy chain variable region (VL), followed by CH1, a hinge, and CH2 and CH3 constant regions.
[0057] As used herein, proteases, such as cathepsin D or L, can cleave antibodies “between” two regions, such as VL and CL or VH and CH (i.e., CH1). In such cases, for example, a cleavage between VL and CL or between VH and CH, this means that the cleavage occurs exactly before, within, or within FR4 of VL or VH, but before the 20th amino acid in the CL or CH (i.e., CH1) segment of the antibody. This is illustrated, for example, in the examples herein. For example, a cleavage occurring between the CH1 and CH2 regions can similarly occur before, within, or after the hinge region, such that one fragment contains most of the CH1 region and the other fragment contains most of the CH2 region.
[0058] As used herein, a protease cleavage site “before,” “before,” “ahead,” or “above” a certain amino acid region or location means that cleavage occurs at the N-terminus of that region or location. Cleavage occurring “after,” “behind,” or “below” a particular location or region refers to C-terminal cleavage at that location or region. Similarly, a region or amino acid location “before,” “ahead,” or “above” another amino acid region or location is at the N-terminus of that other amino acid region or location. A region or amino acid location “after,” “behind,” or “below” another region or location is at the C-terminus of that other region or location.
[0059] "Cetase L" comprises a lysosomal protease expressed in eukaryotic cells and may be naturally occurring or recombinant. Cathepsin L can be derived from a variety of eukaryotes, such as humans or other mammals. Cathepsin L may also include genetically engineered variants of natural cathepsin L that retain cathepsin L activity but may, for example, improve activity, yield, shelf life, or stability. Cathepsin L is also known as cathepsin L1. In some embodiments, cathepsin L is human cathepsin L, such as recombinant human cathepsin L. Mammalian cathepsin L is expressed by the CTSL1 gene. An exemplary human cathepsin L comprises the sequence of SEQ ID NO:10 and is also available from Sigma (catalog number C6854).
[0060] "Cetase D" comprises a lysosomal protease expressed in eukaryotic cells and may be naturally occurring or recombinant. Cathepsin D can be derived from a variety of eukaryotes, such as humans or other mammals. Cathepsin D may also include genetically engineered variants of natural cathepsin D that retain cathepsin D activity but may, for example, improve activity, yield, shelf life, or stability. In some embodiments, cathepsin D is human cathepsin D, such as recombinant human cathepsin D. Mammalian cathepsin D is expressed by the CTSD gene. An exemplary human cathepsin L comprises the sequence of SEQ ID NO:9 and is also available from Sigma (catalog number C8696).
[0061] "De novo" sequencing of a protein or protein fragment refers to determining the sequence of that protein or fragment, such as a full-length antibody molecule or antigen-binding fragment or other antibody fragment, without prior knowledge of the sequence by any other means. In other words, the sequence is determined "from scratch" without relying on any previously known sequence information.
[0062] "Bottom-up" protein sequencing refers to a method in which proteins are digested to form peptides, which are typically short in length or size (e.g., about 3-5 kDa or about 5-30 amino acids), for example with enzymes such as trypsin, and the peptides are analyzed by mass spectrometry and then assembled by software, for example by analyzing overlapping peptides and comparing them with known protein sequences.
[0063] "Top-down" sequencing involves measuring the mass of a whole protein or peptide and then breaking the entire protein down into a series of product ions using mass spectrometry, from which sequence information can be obtained.
[0064] "Middle-to-bottom" sequencing involves breaking down proteins into larger fragments (e.g., approximately 5-25 kDa), which can then be separated and further analyzed using top-to-bottom and / or bottom-to-top methods. This method typically uses proteases to generate these fragments.
[0065] As used herein, “isolation” of one or more protein fragments after an enzyme cleavage reaction means separating at least a portion of the desired protein fragment from other fragments and / or separating at least a portion of the fragment from the enzyme so that the fragment can be sequenced or structurally analyzed without interference from contaminating proteins. In some cases, the desired fragment can be separated during mass spectrometry analysis, while in others, it can be separated at least partially by chromatography, filtration, or other methods.
[0066] "Liquid chromatography" or "LC" refers to the process of separating components by means of the interaction between sample components and a stationary phase (e.g., a particulate material column) and a mobile phase (i.e., body fluid). LC can be performed in one-dimensional (1D-LC) form, which means running a separation process; or it can be performed in two-dimensional (2D-LC) form, which means using a different separation method (such as using a different mobile phase) in a second separation step to further separate the precipitate or a portion thereof from the first separation. LC encompasses, for example, HPLC and reversed-phase HPLC methods. "High-performance liquid chromatography" or "HPLC" refers to a class of LC systems in which a mobile phase is flowed under pressure through a stationary phase (such as a column). HPLC systems can be connected to a detector (such as a mass spectrometer). HPLC processes can be performed in "normal phase" ("NP" or "NP-HPLC") or "reversed phase" ("RP" or "RP-HPLC" or "RPLC"). In RPLC processes, the stationary phase (e.g., a column) is nonpolar, while the mobile phase is polar (such as a water / polar organic solvent mixture or gradient). In normal-phase HPLC, the stationary phase (e.g., a column) is polar and the mobile phase is nonpolar. LC methods also include size exclusion chromatography (SEC), which separates peptides based on size, and methods using phases separated by charge or isoelectric point (pI), such as hydrophobic interaction chromatography (HIC), strong cation exchange (SCX), strong anion exchange (SAX), WSX, and other charge variant interaction phases.
[0067] Mass spectrometry, or MS, is a technique for measuring the mass-to-charge ratio (m / z) of one or more molecules in a sample. As used herein, "tandem MS" or "MS / MS" refers to the movement of a single ion, multiple ions, or the entire mass envelope (precursor) to a lysis chamber, followed by the delivery of the lysis products to a mass analyzer. Depending on the design of the mass spectrometer, lysis events can occur before a single mass analyzer, between two or more different analyzers, or within a single mass analyzer.
[0068] MS analysis may have several options. In some embodiments, the MS instrument does not include a quadrupole. In some embodiments, the MS instrument includes at least one quadrupole. In some embodiments, the MS instrument includes at least two quadrupole analyzers. In some embodiments, the MS instrument includes at least three quadrupole analyzers. In some MS, the detector is an ion trap, quadrupole, orbital trap, or TOF. In some embodiments, the MS instrument or method is multivariate reaction monitoring (MRM), single ion monitoring (SIM), triple quadrupole (TSQ), quadrupole / time-of-flight (QTOF), quadrupole linear ion trap (QTRAP), mixed ion trap / FTMS, time-of-flight / time-of-flight (TOF / TOF), Orbitrap instrument, ion trap instrument, parallel reaction monitoring (PRM), data correlated acquisition (DDA), data independent acquisition (DIA), multistage fragmentation or tandem time MS / MS.
[0069] antibody cleavage
[0070] In some embodiments described herein, antibodies are cleaved using cathepsin L, cathepsin D, or a combination of cathepsin L or D. In some embodiments, antibodies are digested using only cathepsin L without any other enzymes. In some embodiments, antibodies are digested using only cathepsin D without any other enzymes. In some embodiments, antibodies are digested using both cathepsin L and cathepsin D without any other enzymes. In some embodiments, at least one other protease, such as IdeS, is also used to digest antibodies. When both cathepsin L and D are used, these enzymes can be incubated with the antibodies simultaneously (i.e., in a one-pot reaction) or sequentially, one after another.
[0071] In some embodiments, the antibody is an IgG antibody. In some embodiments, the antibody is a human IgG antibody, such as an IgG1, IgG2, IgG3, or IgG4 antibody. In some embodiments, the antibody is a full-length IgG antibody. In some embodiments, the antibody is a full-length human IgG1, IgG2, IgG3, or IgG4 antibody. In some embodiments, the antibody has a full-length light chain and / or a full-length heavy chain. In other embodiments, the antibody does not have a full-length light chain and / or does not have a full-length heavy chain. In some such cases, the antibody contains a light chain comprising a VL region and at least a portion of a CL region. In some such cases, the antibody comprises a VH region and at least a portion of a CH1 region, such as CH1, a hinge, and at least a portion of a CH2 segment, or only CH1 and a hinge, or only CH1, or only the N-terminal portion of CH1. In some embodiments, the antibody is an antigen-binding fragment, such as an F(ab')2 fragment or a Fab fragment.
[0072] In some embodiments, the cleavage reaction is carried out on the antibody in its native state, i.e., where the native antibody retains its folded pattern and any disulfide bonds are intact and unreduced. Therefore, in some embodiments, the antibody is not reduced or denatured. However, in some embodiments, up to 50% organic solvent may be added to relax the antibody state to some extent for optimal cleavage. For example, in some embodiments, 0-30% organic solvent may be added, such as 5-30%, 10-30%, 0-10%, 5-15%, 10-20%, 15-25%, or 20-30%. The organic solvent may comprise, for example, acetonitrile, methanol, ethanol, or isopropanol.
[0073] The cleavage sites of human IgG1 and IgG2B antibodies are as follows: Figure 8 As shown. In the method described herein, both cathepsins L and D can cleave the antibody at one or more sites, including between the VH and CH regions and between the VL and CL regions, to excise VH and VL antibody fragments from the antibody, which respectively contain at least a majority of the VH region and a majority of the VL region. This cleavage also leaves CL and CH fragments containing the C-terminus of the cleavage site. In some embodiments, where the antibody is, for example, human IgG1, both cathepsins L and D also cleave above the antibody hinge region, producing two F(ab') fragments (each containing VL plus CL and VH plus CH1), and another fragment from the heavy chain containing the hinge region and additional constant region sequence segments from the CH2 and CH3 regions. If cleavage occurs at either of these sites, between the variable and constant regions and above the hinge, the result is a set of fragments containing the VL, CL, VH, CH1, and the remaining heavy chain hinge and constant region sequences, as well as a Fab fragment (if the cleavage is incomplete). Similarly, depending on the exact location of the cleavage, the CH1 fragment may contain an amino acid sequence from the C-terminus of the VH region and may not extend all the way to the C-terminus of CH1 as defined by the EU number. Therefore, the fragment may contain the majority of the CH1 region. In other embodiments where the antibody is human IgG2B or IgG4, for example, cathepsin L or D may not cleave above the hinge due to the different disulfide bond structures in the antibody. (See also...) Figure 8 Both cathepsins L and D can further cleave the IgG1 antibody between the CH2 and CH3 regions of the Fc region, such as... Figure 8 As shown, a CH2 fragment and a CH3 fragment are left on either side of the cleavage site. In the method described herein, cathepsin D can also cleave directly below the hinge region, resulting in an F'(ab)2 fragment and an Fc fragment with all or most of the Fc region sequence below the cleavage site. (See...) Figure 8For example, when both enzymes are used to cleave human IgG1 antibodies, a series of fragments corresponding to VL, VH, CL, CH1, CH2, CH3, CL+CH1 (disulfide bond), and F(ab')2 may be generated. In some embodiments, cathepsin D and cathepsin L are combined to generate VL, VH, CL, CH1, CH2, CH3, CL+CH1 (binding), and F(ab') fragments from human IgG1 antibodies. In some embodiments, cleavage with cathepsin L or D, or both cathepsin D and L, leaves VH and VL fragments of approximately 8-16 kDa, such as approximately 10-16 kDa, 10-13 kDa, 10-12 kDa, 10-11 kDa, or 11-12 kDa. In some cases, the length of the VH and VL fragments is approximately 90-120 amino acids, such as approximately 95-110 amino acids. In some cases, simultaneous or missing cuts will produce fragments with various combinations of VL, VH, CL, CH1, CH2, CH3, CL+CH1, and F(ab')2 fragments.
[0074] Examples provided in this article show data demonstrating the cleavage of known antibodies by cathepsin L and / or D. As shown in Table 5a, olibutuzumab was cleaved with cathepsin L at the VH CDR3 and at the ends of the variable portion of the heavy chain. The enzyme cleaved at multiple sites within the heavy chain hinge region. This yielded VH fragments of amino acids 1-99, 1-135, 1-136, 1-137, 1-138, and 1-139, for example, with masses between 10 and 16 kDa, as well as longer light and heavy chain fragments, such as LC fragments of amino acids 1-206 and 1-218 and HC fragments of amino acids 1-220, and LC+HC fragments with masses of 20-25 kDa and 45-50 kDa, respectively (see Table 5a). Exposure to cathepsin D resulted in cleavage of the heavy chain hinge region of olibutuzumab, as shown in Table 5b below. For example, this cleavage produces LC+HC fragments and F(ab')2 fragments with lengths of approximately 220 to 245 amino acids. Tables 7, 8, and 10 show the cleavage sites of trastuzumab, a human IgG1 antibody, similar to olibustatumab. Trastuzumab cleaved with cathepsin L produces a heavy chain fragment (i.e., the VH fragment) of amino acids 1-140 and 1-102, and a light chain fragment of amino acids 1-213, 1-214, and 9-196, as well as a heavy chain fragment of amino acids 100-223 in the CL region (containing the CH1 region) and a light chain fragment of amino acid residues 117-214 (Table 8). Cleavage with cathepsin D produces a similar set of fragments: light chain fragments of residues 1-214 and 1-213, and heavy chain fragments of residues 1-140 and 1-102, as well as a heavy chain fragment containing residues 2-222 and 11-110 (Table 9). Digestion with two enzymes yielded several VL fragments containing residues 1-107, 1-111, and 1-116; a longer LC fragment containing residues 1-202; a VH fragment containing position 1-115; and HC constant region fragments containing amino acids 241-349 and 243-341. Fragments containing combined LC and heavy chain CH1 regions, as well as F(ab') and F(ab')2 fragments, were also produced (Table 10). Eculizumab, a human IgG2B antibody, like olibutuzumab, yields a VH fragment upon exposure to cathepsin L, ending in heavy chain CDR3 and containing amino acids 1-102 to 1-106 of the heavy chain sequence. Table 6 shows that cathepsin D also cleaves eculizumab in VH CDR3 and cleaves F(ab')2 below the hinge region from Fc.
[0075] Therefore, in some embodiments, when used for human IgG1 antibodies, cathepsin L and / or D will cleave between VH and CH and / or between VL and CL, particularly within or just after HC and LC CDR3, producing VH and VL fragments within or just after CDR3. In some embodiments, cathepsin L and / or D will also cleave the antibody between the first and second chain disulfide bonds to produce F(ab'). In some embodiments, cathepsin D will cleave within or just below the heavy chain hinge region to produce the F(ab')2 fragment, which can then be further cleaved, for example, between VH and CH1 portions and / or between VL and CL portions. Furthermore, in some embodiments, both proteases also cleave between CH2 and CH3 to produce CH2 and CH3 fragments along the CH2 domain. Therefore, in some embodiments, cleavage with one or both enzymes will produce fragments containing VH and / or VL comprising respective CDR1, CDR2, and CDR3.
[0076] In some embodiments, cleavage conditions are optimized to achieve higher cleavage efficiency at one or more sites. When cleavage efficiency (also known as digestion efficiency) refers generally to the digestion of a protein or antibody, it is the percentage of the starting antibody that has been cleaved. Cleavage efficiency at specific sites or locations can also be evaluated, such as after the VH and VL regions of the antibody. In some embodiments, relatively low cleavage efficiency at each intended cleavage site is acceptable, such as cleavage efficiency of at least 1% to 50%, for example, to produce a range of fragment sizes. Furthermore, low overall cleavage efficiency is also acceptable when the amount of antibody to be analyzed is relatively large. In other cases, higher cleavage efficiency is required, particularly for sites such as between VH and CH and between VL and CL, to maximize the production of VH and VL antibody fragments. In some embodiments, the overall cleavage efficiency is at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 98%, or at least 99%, or 100%. In some embodiments, the cleavage efficiency after VH and VL is at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 98%, or at least 99%, or 100%. The cleavage efficiency may be affected by factors such as reaction time, temperature, pH, the presence of organic solvents, and the tertiary structure of the antibody.
[0077] This invention comprises a cleavage reaction with cathepsin D and / or L, which produces one or more fragments, including VL, VH, CL, CH1, CH2, CH3, CH2-CH3, CL+CH1 (bonded), F(ab'), and F(ab')2, and resulting compositions comprising those fragments. Thus, for example, the enzymatic cleavage reaction described herein can produce VL and / or VH fragments comprising 90-150 amino acids, such as 95-140, 100-140, or 100-120 amino acids. Such VH and / or VL fragments may have a molecular weight of, for example, 10-16 kDa, such as 10-13 kDa, 10-12 kDa, 10-11 kDa, or 11-12 kDa. Larger fragments of 200-250 amino acids (e.g., bound light and heavy chain fragments) may also be produced, depending on the cleavage efficiency at different sites in the natural antibody. In some embodiments, F(ab') and / or F(ab')2 fragments may also be generated. In some cases, mixtures of all these fragments may be generated. Thus, some cleavage reactions can produce compositions containing at least two of the following ten types of fragments: VL, VH, CL, CH1, CH2, CH3, CH2-CH3, CL+CH1 (bonded), F(ab'), and F(ab')2. Some cleavage reactions can produce compositions containing at least three of the following ten types of fragments: VL, VH, CL, CH1, CH2, CH3, CH2-CH3, CL+CH1 (bonded), F(ab'), and F(ab')2. Some cleavage reactions can produce compositions containing at least two of the following four types of fragments: VL, VH, CL, CH1, CH2, CH3, CH2-CH3, CL+CH1 (bonded), F(ab'), and F(ab')2. Some cleavage reactions can produce compositions containing, for example, 90-150 amino acids of VL and / or VH fragments, and at least two of the following other fragments: CL, CH1, CH2, CH3, CH2-CH3, CL+CH1 (bonded), F(ab') and F(ab')2.
[0078] For example, in some embodiments, the reaction is carried out at pH 2-8, pH 2-7, pH 2-6, pH 2-5, pH 3-6, pH 3-5, pH 3-4, pH 4-5, pH 2, pH 2.5, pH 3, pH 3.5, pH 4, pH 4.5, pH 5, pH 5.5, pH 6, pH 7, or pH 8. In some embodiments, the reaction is carried out at pH 3-5, such as at pH 3, 3.5, 4, 4.5, or 5. In some embodiments, the reaction is carried out at pH 4. The choice of pH may also depend on whether cathepsin L, cathepsin D, or both cathepsin D and L are used.
[0079] In some embodiments, the reaction is carried out at room temperature (approximately 18-25°C) to 50°C. In some embodiments, the reaction is carried out at temperatures of 30-50°C, 30-45°C, 30-37°C, 37-45°C, 40-50°C, or 37-50°C. For example, higher temperatures may shorten the reaction time. In some embodiments, the reaction is carried out for 4-30 hours, such as 4-12 hours, 12-24 hours, or 12-18 hours. In some embodiments, the reaction is carried out at pH 3-5, such as at pH 3, 3.5, 4, 4.5, or 5, and at 37-50°C. In some embodiments, the reaction is carried out at pH 4 and 37°C for 12-24 hours.
[0080] In some embodiments, cathepsin D is human cathepsin D, such as containing the amino acid sequence of SEQ ID NO:9. In some embodiments, cathepsin L is human cathepsin L, such as containing the amino acid sequence of SEQ ID NO:10. In some embodiments, the cleavage reaction is carried out at a ratio of cathepsin D and / or L enzyme to protein of 1:20 to 1:2000. In some embodiments, ratios of 1:20 to 1:500, 1:50 to 1:500, 1:100 to 1:500, 1:200 to 1:1000, 1:200 to 1:2000, 1:500 to 1:2000, 1:1000 to 1:2000, or 1:20, 1:50, 1:100, 1:200, 1:300, 1:400, 1:500, or 1:1000 are used. In some embodiments, changing this ratio can change the degree of cleavage and, in some cases, can affect the efficiency of different cleavage sites. For example, without being bound by theory, reducing the amount of enzyme can not only result in a lower overall cleavage efficiency, but can also affect the resulting cleavage products by prioritizing certain more accessible cleavage sites over others. Therefore, in some embodiments, changing the enzyme-to-protein ratio can affect the distribution of the resulting cleavage products.
[0081] The data in this paper unexpectedly show that the cleavage of cathepsin L and cathepsin D depends on the tertiary structure of the antibody. For example, the cleavage efficiency at certain sites can depend on the folding of molecules near those sites or vary due to disulfide bond patterns. Tertiary structure can block cleavage at sites that would otherwise be cleaved in the denatured antibody. For example, as... Figure 8 As shown, cathepsin D cleavage occurs below the hinge region of human IgG1 antibody, but due to differences in disulfide bond patterns, this cleavage does not occur in human IgG2B or IgG4 antibodies.
[0082] Therefore, in some embodiments, the antibody is cleaved in its native state. An antibody in its "native state" is one that retains its general native folded structure and disulfide bonds; that is, the antibody is undenatured or unfolded, and the disulfide bonds are not reduced. In contrast, bottom-up cleavage is typically performed by digesting the protein to be analyzed in a denatured state, thereby readily generating small peptides from the protein. In some embodiments, as described above, up to 50% of an organic solvent may be added, for example, to relax the antibody state to some extent for optimal cleavage, but to avoid denaturing or unfolding the antibody, thus keeping the antibody in its native state. For example, in some embodiments, 0-30% of an organic solvent may be added, such as 5-30%, 10-30%, 0-10%, 5-15%, 10-20%, 15-25%, or 20-30%. The organic solvent may include, for example, acetonitrile, methanol, ethanol, or isopropanol. In some embodiments, the reaction buffer contains no more than 50% organic solvent. In some embodiments, the reaction buffer contains no more than 30% organic solvent. In some embodiments, the reaction buffer contains no more than 10% organic solvent. Similarly, as mentioned above, in some embodiments, the antibody is not reduced to avoid interfering with its natural disulfide bond pattern.
[0083] In some embodiments, both cathepsin D and cathepsin L are used, with the enzymes exposed to the antibody one after the other; in other embodiments, they are incubated simultaneously with the antibody under the same reaction conditions. In some embodiments, both enzymes are simultaneously added to the antibody in the buffer at pH 3-5, such as pH 3, pH 3.5, pH 4, pH 4.5, or pH 5, and at a temperature of 30-50°C, such as 37°C. In some such cases, 10-30% organic solvent is also added to the reaction mixture. Surprisingly, when both cathepsin D and L were used simultaneously in buffer at pH 3-5, such as pH 3, pH 3.5, pH 4, pH 4.5 or pH 5, and at a temperature of 30-50°C, the cleavage efficiency between VL and CL and between VH and CH of the antibody was observed to be up to 100% (e.g., at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 98% or at least 99%, or 100%).
[0084] For example, in some methods described herein, because cathepsin L / D cleavage appears to be tertiary structure-dependent, the antibody can remain native during cleavage. In some embodiments, the antibody remains native during and after cleavage and during MS analysis. In some methods described herein, the antibody is not treated with denaturing agents or disulfide-reducing agents during or after cleavage. In some methods described herein, the antibody retains its disulfide bonds during and after cleavage. Some methods described herein include mass spectrometry (MS) analysis of one or more antibody fragments after cleavage, wherein the antibody remains native and is not treated with denaturing agents or disulfide-reducing agents prior to MS analysis. Therefore, in some embodiments, in addition to advantageously selecting antibody fragments that may result from the reaction with cathepsin L and / or D, such as VL, VH, F(ab'), F(ab')2, or other fragments, CDR1, CDR2, and CDR3 containing heavy or light chains, can be directly analyzed by MS after cleavage without denaturing or reducing the disulfide bonds in the resulting antibody fragment.
[0085] After the antibody is cleaved, it can be treated to remove one or more enzymes and alter the buffer solution, and / or separate specific fragments.
[0086] Post-cutting treatment can be selected arbitrarily.
[0087] The antibody fragments generated during the cleavage process can be further processed in a variety of ways before mass spectrometry analysis.
[0088] In some embodiments, antibody fragments may be treated to reduce disulfide bonds. During disulfide bond reduction, for example, certain fragments containing two polypeptide segments linked by disulfide bonds may dissociate into two separate substances. In some cases, a portion of the cleaved antibody may be evaluated by mass spectrometry without reducing the SS bonds, while another portion may be reduced prior to evaluation, for example, allowing top-down analysis of the reduced and unreduced fragments to obtain further data. In some embodiments, the resulting fragments may be alkylated or otherwise chemically modified.
[0089] In some embodiments, after cleavage, the resulting fragments can be separated from the enzyme reaction mixture in various ways. For example, fragments can be separated by chromatography or size filtration. For example, fragments can be separated by capillary electrophoresis or liquid chromatography. Alternatively, fragments can be separated from other components by filtration, such as using a molecular weight cutoff filter that retains higher molecular weight substances but allows smaller substances (such as certain cleavage fragments) to pass through. In some embodiments, for example, if the desired fragment is, for example, below 25 kDa, such as about 10-14 kDa, a molecular weight cutoff filter, such as a 20 kDa or 30 kDa filter, can be used to separate the desired fragment from larger fragments, after which optionally a concentration step of the flow-through is performed on a MW filter that retains the fragment of interest. If desired, a relatively low molecular weight cutoff filter can also be used to separate the desired fragment from smaller fragments or buffer contaminants, such as a filter that retains molecules above 3 kDa or above 10 kDa.
[0090] The cleaved antibody fragments can also be separated from the enzyme reaction mixture by exchanging buffers, such as changing the pH and other buffer conditions. This can occur, for example, during chromatography or filtration. In some embodiments, the fragments can be analyzed by Adammann degradation, optionally combined with further enzymatic or MS cleavage, as an alternative to obtaining or validating their sequence.
[0091] In the embodiments described herein, any combination of the above processes may be used.
[0092] Mass spectrometry analysis
[0093] To obtain sequence or structural information about antibody fragments, at least one fragment may be analyzed by mass spectrometry. In some embodiments, VH and / or VL fragments cleaved by cathepsin L or D, or both cathepsin L and D, are analyzed by MS. In some embodiments, at least one of the resulting fragments is analyzed using a top-down method. In some embodiments, a bottom-up method is used. In some embodiments, a combination of top-down and bottom-up methods is used.
[0094] In some embodiments, the complete sequence of at least one fragment is obtained. In other embodiments, the sequence of at least 10 amino acid extensions is obtained. In some embodiments, the sequence of at least 15 amino acid extensions is obtained. In some embodiments, the sequence of at least 25 amino acid extensions is obtained. In some cases, the sequence of at least 50 amino acid extensions is obtained. In some cases, the sequence of extensions of 10-50, 15-50, 25-50, or 10-25 amino acids is obtained. In some cases, the CDR3 sequence of the VH or VL fragment is obtained. In some cases, the CDR1, CDR2, and / or CDR3 sequences of the VH or VL fragment are obtained. In some embodiments, the sequence of the antibody fragment is unknown prior to this method, and therefore, the method obtains the sequence or a portion of the fragment de novo.
[0095] MS measures the mass-to-charge ratio (m / z) of one or more molecules in a sample. Tandem MS is used in some embodiments and is a method by which a single ion, multiple ions, or an entire mass envelope (precursor) is moved to a lysis chamber and then the lysis products are sent to a mass analyzer. Depending on the design of the mass spectrometer, the lysis event may occur before a single mass analyzer, between two or more different analyzers, or within a single mass analyzer.
[0096] MS analysis may have several options. In some embodiments, the MS instrument does not include a quadrupole. In some embodiments, the MS instrument includes at least one quadrupole. In some embodiments, the MS instrument includes at least two quadrupole analyzers. In some embodiments, the MS instrument includes at least three quadrupole analyzers. In some MS instruments, the detector is an ion trap, quadrupole, or orbitrap. TM Or time-of-flight (TOF). In some embodiments, the MS instrument or method is multivariate reaction monitoring (MRM), single-ion monitoring (SIM), triple quadrupole (TSQ), quadrupole / time-of-flight (QTOF), quadrupole linear ion trap (QTRAP), hybrid ion trap / FTMS, time-of-flight / time-of-flight (TOF / TOF), Orbitrap instrument, ion trap instrument, parallel reaction monitoring (PRM), data correlation acquisition (DDA), data independent acquisition (DIA), multistage fragmentation or tandem time MS / MS. In some embodiments, the mass spectrometer includes at least one quadrupole and uses a dissociation method selected from: collision-induced dissociation (CID), high-energy collision dissociation (HCD), electron capture dissociation (ECD), electron transfer dissociation (ETD), electron transfer / high-energy collision dissociation (EThcD), or photodissociation, such as UV photodissociation (UVPD).
[0097] In some embodiments, direct injection, static spray injection, or flow injection mass spectrometry is used to analyze one or more antibody fragments. In some cases, injection is performed directly after an enzymatic cleavage reaction or after a buffer exchange step following the cleavage reaction. For example, in some cases, injection is an alternative method to separating the desired fragment via a technique such as chromatography followed by mass spectrometry (such as LC-MS). In the injection method, a sample containing one or more antibody fragments can be directly introduced into the mass spectrometer instrument for lysis by electrospray or nanospray ionization. Precursor ions can then optionally be separated by a quadrupole mass filter for mass measurement and analysis, and lysis can be performed for amino acid sequence prediction.
[0098] Top-down and / or bottom-up analysis
[0099] In some embodiments of this document, mass spectrometry is used for top-down sequence analysis. For example, a mass spectrometer can be used to further cleave diced antibody fragments into a series of product ions, from which their sequences can be predicted. An example is shown in Table 13 below. Related software can be used to align the predicted sequences. As illustrated in the example, for instance, in... Figure 14A and 14B An example is illustrated below. For instance, in the case of VH or VL fragments, since these fragments typically begin with the native N-terminal amino acid of the antibody being analyzed, mass spectrometry sequence information can be unconvoluted and aligned starting from the N-terminus of the fragment. Therefore, the N-terminus can serve as a reference point for aligning product ions generated during the mass spectrometry process. For example, when analyzing VH or VL, since these fragments are located at the N-terminus of the antibody polypeptide chain, the product ions generated in MS analysis can be aligned starting from the N-terminus. For this and other reasons, the enzyme does not need to specifically cleave at individual amino acids to form the C-terminus of the fragment.
[0100] Various software packages can be used to deconvolve and align sequence information from top-down MS analysis. Examples include PEAKs. TM (Bioinformatics Solutions, Inc.) and Byos TM And its component software (Protein Metrics, Cupertino, CA, USA).
[0101] In some embodiments, the methods described herein can be combined with additional middle-to-bottom and bottom-to-top methods for further sequence analysis. For example, cleavage with cathepsin L and / or D can be combined with cleavage by other enzymes, such as proteases from Streptococcus pyogenes (IdeS) (e.g., Fabricator), cleavage within or near the antibody hinge region. TM (Genovis, Inc.) or Gingis Khan TM(Genovis). In some embodiments, cathepsin L, cathepsin D, or a combination of cathepsin L and D may be used with IdeS or Gingis Khan. TM (Genovis) combination. In some embodiments, other proteases, such as trypsin, papain, chymotrypsin, or other proteases, may be combined with cathepsin L, cathepsin D, or cathepsin L and D. The products from such cleavage reactions can then be analyzed, for example, by a top-down or bottom-up approach.
[0102] In some embodiments, fragments generated by cathepsin L and / or D cleavage reactions can be further analyzed using a bottom-up approach. Therefore, in some embodiments, for example, the resulting fragments may be reduced or denatured and then further cleaved with a protease, such as trypsin or papain, to produce smaller fragments for MS analysis. In some embodiments, top-down analysis may be combined with bottom-up analysis, for example, as a means of validating and cross-checking sequence information.
[0103] De novo antibody sequencing workflow
[0104] In some embodiments, the methods described herein can be used for partial or complete de novo sequence analysis of one or more antibody fragments. Typically, de novo determination of sequence extensions requires complete cleavage of the extension during mass spectrometry analysis, i.e., cleavage after each subsequent amino acid in the extension, so that the mass of each consecutive amino acid residue can be determined and thus the amino acid residues identified. Depending on the chosen cleavage method, disulfide bond reduction can be performed prior to mass spectrometry analysis to ensure complete cleavage of specific amino acid extensions. For example, if Orbitrap with high-energy collisional dissociation (HCD) is used… TM Lysis may require reduction to obtain cleavage after each consecutive residue. In other cases, de novo sequencing can be performed without prior disulfide bond reduction. In other embodiments, a portion of a sample containing antibody fragments can be analyzed without reduction, and another portion of the sample can be analyzed after reduction.
[0105] For example, Figure 14A The figure shows a depiction of the variable region of the trastuzumab light chain after MS cleavage. As shown, a continuous γ-ion appears at residues H91-E105. Therefore, this portion of the VL roughly corresponding to the CDR3 region can be determined by top-down analysis. Such top-down analysis can use commercially available software, such as PEAKS, to determine the amino acid sequence using mass data and fragment alignment. TM (Bioinformatics Solutions, Inc.) or Supernovo TM(ProteinMetrics), or open-source programs. To determine the sequence of additional portions of antibody fragments, such as VL fragments, additional cleavage frequencies can be used so that cleavage occurs after all or almost all amino acid residues in the fragment molecule. Additionally, antibody cleavage products can be processed to reduce disulfide bonds, so that disulfide bonds do not interfere with cleavage. To sequence larger segments of antibody fragments, commercially available software parameters can be adjusted to allow de novo sequencing of fragments, for example, up to approximately 12 kDa. For example, the allowed total peptide length in the program can be extended, the error tolerance allowed at the MS1 level can be increased, and the incorporation of disulfide bond rules can be enabled, for example, by modifying the p-score or A-score. Furthermore, in some embodiments, candidate de novo sequences can be validated by using more than one software program to determine the sequence.
[0106] reagent kits and products
[0107] The present invention also includes kits and products for optimizing antibody cleavage reactions using cathepsin L, cathepsin D, or cathepsin L and D. In some embodiments, the kit contains cathepsin L. In some embodiments, the kit contains cathepsin D. In some embodiments, the kit contains cathepsin L and cathepsin D. In some embodiments, in addition to cathepsin L and / or D, the kit contains one or more additional enzymes, such as IdeS, papain, trypsin, chymotrypsin, or Gingis Khan. TMIn some embodiments, the kit comprises one or more reaction buffers for cathepsin L and / or cathepsin D cleavage reactions. In some embodiments, the kit comprises one or more reaction buffers at pH 2-8, pH 2-7, pH 2-6, pH 2-5, pH 3-6, pH 3-5, pH 3-4, pH 4-5, pH 2, pH 2.5, pH 3, pH 3.5, pH 4, pH 4.5, pH 5, pH 5.5, pH 6, pH 7, or pH 8. In some embodiments, the reaction buffer has a pH of 3-5, such as pH 3, 3.5, 4, 4.5, or 5. In some embodiments, the reaction buffer has a pH of 4. In some embodiments, the reaction buffer contains one or more organic solvents. In some embodiments, the organic solvent is methanol, ethanol, isopropanol, or acetonitrile. In some embodiments, the reaction buffer contains 5-50% organic solvent, such as 5-30%, 10-30%, 0-10%, 5-15%, 10-20%, 15-25%, or 20-30%. In some embodiments, the reaction buffer contains no more than 50% organic solvent. In some embodiments, the reaction buffer contains no more than 30% organic solvent. In some embodiments, the reaction buffer contains no more than 10% organic solvent. In some embodiments, the product or kit also includes instructions for use for performing cathepsin D and / or cathepsin L cleavage reactions on the antibody composition.
[0108] Example
[0109] Example 1
[0110] Despite the tremendous success of proteomics in protein sequencing, complete sequencing of antibodies (Abs) remains a significant challenge [1,2]. The goal is to annotate and validate the position and sequence of individual amino acids (and any variants), currently requiring the use of 4–5 different proteases to generate overlapping peptides of ideal length for bottom-up proteomics analysis using liquid chromatography (LC)-mass spectrometry (MS). This represents a higher standard of analysis compared to a simple monoclonal check performed by complete analysis or protein validation, typically using a single enzyme digestion. If de novo annotation is used, these mass spectra must be processed via specialized Ab sequencing procedures that utilize information about the extraction mass shift between product ion peaks. Assignments are based on computational rules that limit permissible mass errors, making the success of such analyses highly dependent on the superior quality of the MS / MS spectra [3–7].
[0111] Alternatively, one can begin exploring top-to-bottom enzymatic proteomics approaches, where antibodies are first cleaved above or below the hinge region to produce Ab protein fragments that can be modified for sequencing via top-to-bottom and / or top-to-bottom proteomics [8-10]. In these approaches, F(ab')2, F(ab'), Fc, Fd, light chain (LC), and heavy chain (HC) fragments can be selectively generated depending on the protease or denaturant used, particularly proteases from *Streptococcus pyogenes* (e.g., *Fabricator*). TM (Genovis, Inc.) has become very popular [10-13]. IdeS is a protease that digests antibodies at a specific site just below the hinge, producing a homologous library of F(ab')2 and Fc / 2 fragments [12,13].
[0112] The main difference between top-down and bottom-up sequencing methods lies in their use of relatively high molecular weight (HMW) precursors (5-25 kDa). These protein fragment precursors provide corresponding sequences to which all fragment ions can and should be mapped. Combined with complete MS1 information from different fragments, especially at high resolution, top-down and mid-down proteomics methods can be very powerful [8-11, 14-21].
[0113] The combination of native mass spectrometry [22-28] with top-down proteomics [14,16,20,29,30] offers additional advantages for the analysis of biotherapeutic drugs. LC separation of complex digested mixtures is often inadequate, leading to co-elution of substances, and these masses frequently overlap under denaturing conditions, reducing the signal-to-noise ratio and limiting accurate mass deconvolution. Similarly, while higher charge states in top-down analysis improve high-collision-energy dissociation (HCD) cleavage efficiency, native mass spectrometry allows for large separation widths that include multiple charge states when proteins are moved to a less crowded m / z space [31,32]. This results in increased product ion signal-to-noise ratios, higher coverage, and simplified workflows. Typically, top-down cleavage of large, intact proteins with non-reduced disulfide bonds (>25 kDa) lacks sufficient coverage to be applied de novo on current industry-standard MS instruments, which are traditionally time-of-flight instruments with collision-induced dissociation or Orbitrap instruments with HCD
[31] . These lack electron-induced dissociation, an efficient orthogonal cleavage method [14,18,33-36], and UV dissociation, which is also suitable for very large peptides [16,17,30]. Without multiple cleavage methods, incomplete coverage will limit both top-down and mid-down applications. Therefore, there is an unmet need for more and alternative mid-down workflows that utilize proteases that have not yet been adequately explored to produce protein fragments more suitable for standard LC-MS / MS HCD experiments.
[0114] In the field of IgG analysis, the most commonly used middle-to-bottom proteolytic enzyme is IdeS, which preferentially cleaves at a single site below the hinge region [12,13], and GingisKHAN. TM (Genovis, Inc.)
[37] , which cuts above the hinge. Most alternative middle-to-bottom digestions attempt to control the rate of mixed enzymatic or chemical degradation so that the size of the peptide is related to the time the protein is exposed to the enzyme. Recently, the acidic protease of Aspergillus saitoi has been immobilized on an electrospray emitter for use in online peptide mapping analysis[38,39]. In exploratory work, peptides of 3-15 kDa were produced at a ratio of 1:5 over an exposure time of 0-2 minutes. Similarly, pepsin activity was intentionally limited via pH deoptimization to produce middle-to-bottom-sized fragments and F(ab')2 domains
[40] . In addition, peptides produced by proteases OmpT
[41] and Sap9
[42] are typically in the 1.5-15 kDa range, which is larger than the average trypsin peptide size.
[0115] Commercially available lysosomal peptidases cathepsin L[43,44] and D
[45] have been reported in the literature as two proteases with unpredictable cleavage sites. Cathepsins represent a family of enzymes found in lysosomes that are responsible for the degradation of proteins via the hydrolysis of the protein backbone
[46] . Cathepsin L is a member of the peptidases C1 family and has been reported to cleave after the F,R or R,R sites of P2 and P1[47-52], while cathepsin D has been reported to be an aspartic protease that cleaves between hydrophobic residues, particularly between Leu and Phe, although these preferences are contradictory in the cited literature[47,53-57]. These studies have primarily involved protein standards, extracts, and peptides using SDS-PAGE, protein sequencers, or peptide substrate microarrays. A common thread in these studies is that, despite the heterogeneity of the enzymes, the number of fragments produced is surprisingly limited. The degradation rate of proteases varies depending on enzyme isomers, protein sequence, secondary and tertiary structures, buffer composition (especially metals such as copper) and storage conditions
[58] .
[0116] The evaluation of novel enzymes, especially when digestion site restrictions are minimal, is challenging because numerous internal fragments can be generated at any location and size within the target protein. This large computational space is further expanded when potential interchain disulfide bonds or post-translational modifications (such as glycans found on the Fc) are included. The work described in this paper utilizes Intact Mass... TM Algorithm
[59] is used to specifically map the cathepsin digestion of Ab, and this algorithm was updated in 2019 to include automatic annotation of the cleaved material. The algorithm is described in further detail in the Methods section.
[0117] Here, we began exploring the cleavage sites of cathepsins L and D using a single standard digestion condition when targeting three IgG1 antibodies (trastuzumab, rituximab, and olibutuzumab), one IgG2 / 4 antibody (eculizumab), and one IgG1 bispecific antibody with protrusion-in-pore modification (anti-Her2 / anti-CD3). The resulting Ab fragments were analyzed directly by high-resolution native mass spectrometry and denaturing LC-MS. The cleavage sites of cathepsins L and D were explored under different pH, temperature, and denaturing (organic percentage) conditions and subsequently optimized to maximize cleavage between the variable and constant regions of the Ab. Our most interesting finding was that we could specifically generate an approximately 12 kDa fragment containing the complementarity-determining region (CDR) of the Ab light chain. To our knowledge, this is the first demonstration of a middle-to-bottom technique directly targeting a highly variable region of the Ab, and we were able to maximize coverage of this region by cleaving this 12 kDa fragment using standard HCD.
[0118] A. Result
[0119] A.1. Mapping cathepsin L and cathepsin D cleavage sites across antibody classes
[0120] This study evaluated the cleavage sites of cathepsin L and cathepsin D in five antibodies (Abs) to identify common digestive motifs and assess differences between IgG1 and IgG2 subtypes. To our knowledge, this is the first report on cathepsin L and D digestion of intact Abs and the first collaborative effort to study sites across Abs with similar or dissimilar homology.
[0121] Protein fragments found in the digest were identified using Intact Mass and manually validated. The molecular weight range of the unconvoluted protein fragment peaks of the two cathepsins and all Abs was 9–98 kDa (Tables 1–9, Figures 1–6). Figures 7 and 1 show examples of automated dispensing of rituximab upon cleavage by cathepsin D. Under the initially selected conditions (pH 7, 2 days incubation), the enzymatic efficiency of cathepsins L and D was found to be quite low, approximately 1%. Although the size distribution of protein fragments spanned a large molecular weight (MW) range, only four major types were observed, corresponding to the following cleavages: between VL and CL, between VH1 and CH1, CH1 between the first and second interchain bonds, and immediately following the hinge region (at a position almost identical to the IdeS cleavage site). At lower abundances, multiple cleavages of the entire HC were observed (Table 1).
[0122] It should be noted that the quality shown in Figure 1 may differ slightly from the quality given in the tables disclosed herein (e.g., 9964.1 above and 9963.45 in Table 2 represent the same peak), because the exact average quality depends on the time, quality, resolution, signal-to-noise ratio, and m / z range used in charge deconvolution, as well as other parameters. Similarly, the quality in Figures 2-6 may also differ slightly from the quality given in the tables disclosed herein, because the exact quality depends on the time, quality, and m / z range used in charge deconvolution, as well as other parameters.
[0123] When all low-intensity signals are included, a large number of total peaks are deconvolved, reflecting the diversity of cut points locally relative to globally. For example, in Figure 7B The results show that cathepsin D can cleave at approximately 14 different but consecutive amino acids to produce F(ab'), many of which are produced with nearly equal probability based on their relative signal intensity (Tables 2 and 3). Within this specific region, cleavage is shown to occur after C, D, K, T, or H. Further reflecting the diversity of local cleavage, some products were found to be the result of asymmetric shearing rather than simple single-point cleavage. For example, as... Figure 7AAs shown, the peak at 97,538 Da is designated as a complex of two LCs plus a heavy chain (E1-F244), which differs from the second HC (E1-V243) by one amino acid. Support for asymmetric cleavage partitioning is provided in the top-down analysis section. Given the lack of amino acid enrichment found in all identified peptides within the -4 to +4 cleavage site motifs (Tables 1-3), this supports the hypothesis that the specificity of cathepsin D may be influenced by secondary and tertiary structures as much as the primary sequence, and this effect will be discussed in the digestion optimization experiments. Similar to Figures 1-6, the mass values shown in Figure 7 may differ slightly from those given in the tables disclosed herein, as the precise mass depends on the time, mass, and m / z range used for charge deconvolution, as well as other parameters.
[0124] Figure 8 A graphical overview of the cleavage sites observed when mapped to schematic diagrams of antibodies with IgG1 and IgG2-B disulfide bond patterns is provided. Although the cleavage sites vary depending on the Ab and cathepsin used (Tables 1-9), some rules apply without exception to all IgG1: (1) cleavage occurs directly after HC and LC CDR3 by cathepsins L and D; (2) cathepsin D cleaves between the disulfide bonds of the first and second chains to produce F(ab'), but cathepsin L does not; (3) the heavy chain hinge is susceptible to alternative cleavage by the two proteases directly below the hinge region, resulting in F(ab')2 and (4) cleavage sites of cathepsins L and D are identified between CH2 and CH3.
[0125] Compared to IgG1, ekuzumab exhibits the same F(ab') cleavage pattern, but lacks a significant cleavage site within the hinge. Therefore, only F(ab')2 and F(ab') were observed. This difference further supports the role of tertiary structure in mediating cathepsin D and L digestion products.
[0126] A.2. Quantitative optimization of digestion efficiency and fragment allocation
[0127] Although it was impossible to predict whether cathepsins D and L would cleave proteins at specific sites or whether these enzymes would be more mixed, we found that cathepsins L and D specifically cleaved Ab at four major sites. This specificity demonstrates the great potential of using cathepsins D and L in a middle-to-bottom sequencing workflow. However, digestion efficiency was quite poor under standard conditions. To improve digestion efficiency, we chose pH as a digestion variable [60,61]. Similarly, the amount of organic solvent was also evaluated, as the tertiary structure of the Ab is thought to affect cleavage. Finally, digestion tests were performed at 37°C or 50°C. Three replicates were performed, and the ratio of the charge state of the intact trastuzumab to the total strength of the digested fragment was compared. Figure 9ACompared to nESI implantation, LC-UV-MS is used to minimize ion suppression of co-ionized substances and improve relative quantification. The ratio of the sum of UV peak areas to Ab peak areas was also calculated using the peptide elution region. Figure 9B Quantification is performed to ensure consistent results.
[0128] The optimal pH efficiency for cathepsin L was determined to be pH 3, and the optimal pH efficiency for cathepsin D was pH 5 (see [reference]). Figure 9A and 9B The trend was supported by MS and UV data. Runs at 50% methanol showed increased efficiency for both enzymes, but significantly increased variability compared to other conditions, likely due to the relative instability of Abs under these conditions. Physical observations indicated turbidity in some 50% methanol samples, possibly due to Ab precipitation but protein fragment dissolution leading to increased digestibility and variability. At lower methanol levels (10% or 30%), no difference in digestibility compared to the control was observed by MS or UV. No conclusions could be drawn regarding the effect of temperature, as data from UV and MS directly contradicted each other for cathepsins L and D. Under all conditions, the observed protein fragments were highly consistent with those reported in the IgG1 control study. For example, a mass of 11,197 Da was detected in all IgG1 samples, representing a low abundance (<1e4) of the HC peptide E1-D102.
[0129] Based on the trends observed under different pH, temperature, and organic matter percentage conditions, the single method was optimized. A one-pot digest of trastuzumab was prepared using cathepsins L and D at 37°C and pH 4 for 18 hours. As shown in Figure 10, 100% digestion efficiency was achieved. The most abundant substance in the sample corresponded to the loss of the CH2+CH3 region and the generation of F(ab')2 (≈98 kDa). Substances smaller than 50 kDa were partitioned within 2 Da, and substances smaller than 100 kDa were partitioned within 4 Da, with a mean error of 31.8 ppm. Observed peptides appeared in all digest replicates (N=6) within 1 Da. The most abundant smaller MW peptides observed were mapped to the VH1, VL, and Cl regions (Table 10).
[0130] Interestingly, the 47 kDa substance characterized in the control study was not observed in the LC-MS analysis of the optimized digest. Figure 7B Although the substance was later observed during nESI injection for top-down analysis, Figure 11D Because F(ab')2 has a wide elution width (about 1 minute) and shows a leading edge, F(ab') may be co-eluted.
[0131] Highly specific cleavage sites were observed throughout the protein by LC-MS. This yielded nine peptides, including a 98 kDa substance, which accounted for approximately 70% of the total intensity of all unconvolutional LC peaks (assigned + unassigned). The remaining protein fragments were observed but unassigned, primarily belonging to the 4–5 kDa low molecular weight group. As the larger peptides provided 100% antibody coverage, assignment of the 4–5 kDa species was not attempted, but a complete list is provided in Table 11. Furthermore, at lower molecular weights, the number of possible sequence assignments increased significantly due to consideration of internal digestion products, and maintaining the integrity of identified sites was important.
[0132] To confirm the specificity of the nine peptides identified, adelman degradation was performed. For seven of the nine identified protein fragments, the sequences were definitively confirmed. Figure 12 Motifs beginning with “PT” and “APxxK” were observed, corresponding to crosslinking masses producing a mass of 22,517.13 Da. Although low abundance and overlapping gel bands ruled out confirmation of a mass of 12,488.77, protein fragments beginning with at least Gly were identified at the expected molecular weight.
[0133] A.3. Top-down analysis of the cut protein fragments
[0134] Top-down analysis was performed to demonstrate the applicability of peptide size and structure to cleavage and to provide further validation of the annotated trastuzumab protein fragments (Table 10). To enhance the signal-to-noise ratio of MS2 spectra, optimized trastuzumab samples were injected onto Q Exactive UHMR via nESI relative to LC, with at least 100 scans of the precursor (Figure 11). Product ions were isotopically separated at a resolution of 200,000 (Figure 13).
[0135] Product ion partitioning was performed as follows: Single isotopic masses were extracted using the Xtract algorithm in Freestyle 1.6 (Thermo Fisher Scientific, Bremen, Germany) and matched within 10 ppm with the preferred predicted sequences in ProSight Lite (Table 10)
[62] , where cysteine was considered to have H loss to explain the presence of disulfide bonds. Subsequently, an internal database was built to account for γ-ion NH3 loss and water loss and matched with the remaining extracted masses (Table 12). Figure 14A As shown, good sequence coverage was achieved at the N- and C-termini of the 12,121.5 Da precursor, with reduced cleavage efficiency between disulfide bonds. The largest product ions (Y104 and B109) were retained to verify sequence allocation. Overall, a sequence coverage of 29.4% was obtained.
[0136] For substance 97,630, the partitioning becomes complex due to the large number of disulfide bonds in the subunits. While interchain and / or intrachain partitioning can be reduced to improve coverage, it is important to verify the binding form of the polypeptide to demonstrate the presence of asymmetric HC cleavage (pairing of PAPELLG.G and PAPELLGG.PSV). Figure 14B As shown, a large number of γ ions specifically correspond to each HC form. After assigning standard γ, b, ammonia, and water loss ions, the presence of cross-linking substances from interconnecting chains was evaluated (Table 13). For LC, modifications constructed from the HC sequence NVNHKPSNTKVDKKVEPKSCDKTHT were considered, with C24 included as a cross-linking site in each subsequence. The considered N and C terminal boundaries represent the starting points of intra-chain disulfide bonds (C148-C204) or inter-chain disulfide bonds (chain 1, C230-chain 2, C230), respectively. For HC, cross-linking modifications were considered from the LC sequence EVTHQGLSSPVTKSFNRGEC, which begins with the amino acid following the last intra-chain cysteine and then cross-links at the C-terminus. Ions detected from these substances confirmed the presence of asymmetric C-termini generated by cathepsin L / D digestion ( Figure 14B A total of 228 ions were detected, with an overall coverage of 33.7%, of which LC coverage was 26.6% and HC coverage was 40%.
[0137] A.4 Application of Optimized Cathepsin L and D Protocols in Bispecific Antibodies
[0138] After the optimization scheme was established, the application of cathepsins on bispecific IgG1 antibodies (anti-Her2 / anti-CD3) was further tested. Although the bispecific antibody has the same disulfide bond structure as IgG1, it exhibits significant structural differences. By mutating various amino acids in the Fc region, a “protrusion and pore” structure was generated, thereby enhancing the xHer2 and xCD3 chains and producing heterodimers
[63] . Changes in primary structure drove this process, with multiple mutations found between amino acids 26-110 (variable region, CD3 binding), in local 371 and 408 (protrusion / pore), and at 297 (preventing glycosylation). In addition, using the newly expressed study antibody, a new source of variability was introduced - the presence of 4% dimers - which are not found in most clinically used pharmaceutical products.
[0139] The cathepsins behaved as expected throughout the F(ab') chain (Table 4). In xHer2 and xCD3 LC and HC chains, cleavage was observed immediately after CDR3 and outside the disulfide bond region. The LC and CH1 constant regions were homologous, and a single protein fragment was designated as the digestion product of both chains. Cleavage after the hinge yielded five protein fragments, with asymmetric cleavage occurring along a highly favored and conserved GGPSVFLFPPK sequence. Interestingly, no further cleavage was observed within the xCD3 CH2 or CH3 region. In the anti-Her2 (protrusion) chain, digestion occurred after the hinge to produce F(ab')2 (AA 1-239), and then several amino acids later to produce the CH2+CH3 fragment (AA 261-436). Multiple protein fragments in CH3 were also produced in the protrusion chain. However, the only Fc region cleaved on the xCD3 strand occurred simultaneously on both chains. Given the considerable heterogeneity of cathepsins, the most likely explanation for this difference is the specific tertiary structure of the bispecific antibody. Compared to protrusions, the rigidity of the pore's shape or structure may make it difficult for cathepsins to "work" in this region until they are at least partially exposed via cleavage of the xHer2 chain. Validating this specific protrusion / pore effect would require testing a large number of bispecificities, which is beyond the scope of this study. These structural effects can also influence digestion efficiency. While the optimized protocol resulted in 100% digestion of trastuzumab, 20% of the complete bispecificity was retained (based on the peak intensity of deconvolution). This could reflect slower digestion due to the unique structure, or in part, slower digestion of the dimer, with the final digestion showing a reduction in dimer content from 4% to 0%.
[0140] B. Discussion
[0141] Developing a mid-to-bottom approach to produce peptides of ideal size for MS sequencing is crucial for advancing the top-to-bottom antibody sequencing workflow. Cathepsins L and D provide an efficient, commercially available, and inexpensive one-pot digestion method to directly achieve this workflow.
[0142] Peptides covering VL, VH, CL, CH1, CH2, CH3, CL+CH1 (bonded), and F(AB') were observed under all digestion conditions. A combination of Adammann degradation (N-terminal confirmation), intact quality (<40 ppm matching), and top-down data definitively and successfully sequenced the major cleavage products generated from the digest, which accounted for 70% of the total protein signal in the optimized sample. The VL and VH regions were generated in high abundance, with cleavage occurring directly after CDR3. This region represents the most challenging sequencing segment due to its high variability within short regions. A key feature of the proposed mid-to-bottom approach is its ability to directly sequence long reads of ideal size for top-down sequencing, including CDR1, CDR2, and CDR3.
[0143] Compared to the most widely used IdeS protocol, both treatments directly generate F(ab'), and the cleavage sites at the hinge are almost identical between the two protocols. Reducing reagents can be used in the IdeS protocol to generate free LC or HC, but such reagents pose a size-related challenge for top-down sequencing via CID or HCD, whereas the cathepsin protocol provides a direct method for protein fragment generation. When combined with existing de novo bottom-up techniques, protein fragment generation allows for region-based checks of sequence quality on the Ab, rather than on the entire intact Ab. This provides an opportunity to quickly find and locate problematic allocations. As computational tools have evolved for top-down de novo sequencing, the cathepsin approach has addressed many sequencing alignment challenges where digests remain within a size range to produce high-quality product ion spectra.
[0144] HCD is known to produce limited sequence coverage of Abs across disulfide bonds
[20] . Alternative cleavage techniques, such as electron capture dissociation (ECD), address this sequencing challenge and can directly analyze digested mixtures, but are not available on many mass spectrometers. Top-down HCD can achieve 100% coverage of smaller molecular weight substances when disulfide bonds are absent. Therefore, if this method is used for de novo Ab sequencing, fractionation of samples by chromatography or molecular weight cutoff filters, followed by treatment and purification of guanidine hydrochloride, will enable deeper sequencing while limiting the number of co-ionization peaks, compared to sequence validation presented in this paper. In addition, the application of guanidine will convert the precursor to a higher charge state, which will further improve cleavage efficiency.
[0145] Evaluation of cathepsins L and D in Ab showed significant concordance in cleavage sites across all IgG1, especially when motif confounding was considered. Fifty unique cleavage sites were identified in all tested antibodies (trastuzumab, rituximab, olibutuzumab, eculizumab, and bispecific antibodies), including combined L / D digests. Cathepsin L cleaved at 27 sites, and cathepsin D at 28 sites. While there was clear evidence that neutral sites were more suitable for cleavage, both cathepsins also showed little preference for specific amino acids at p4 to p4' (Figure 15). Although F and R are commonly reported as cleavage sites for cathepsin L in the literature, and these ends are present, they account for no more than 10% of the total cleavage products. Compared to a 2011 study of cathepsin L activity in HEK293 protein extract, this study found equal enrichment among 4–6 amino acids at each p3–p3' site, with Ab showing a significantly reduced motif bias, suggesting that higher-order structures may be more important than secondary structures
[48] . This may explain why individual studies examining cathepsin L and D protein activity have indeed identified many exceptions to these rules at their reported cleavage sites [47–57]. Another possibility is that studies have used different cathepsin L and D isoforms, which are known to produce different products
[52] . Furthermore, cathepsin L and D have been shown to have the ability to cleave at proline, which is relatively uncommon among all proteases. This is a clear exception
[64] .
[0146] The cathepsin-induced cleavage sites on the ab were compared with their crystal structures to examine the potential roles of secondary and tertiary structures. Figure 16No cleavage was observed within any α-helix, and the vast majority were located in random coils. Remaining cleavage sites were observed within 1–2 amino acids from the end of the random coil, but within the origin of the β-sheet. The nature of these sites strongly suggests that cathepsins L and D have limited ability to cleave within ordered regions of Ab, but can bind to almost any amino acid motif in both flexible and disordered regions. The cleavage sites are further restricted by the disulfide bond pattern. Disulfide bonds significantly restrict the final tertiary structure, offering much less flexibility compared to regions without bound pairs
[65] . While cathepsins can be heterogeneous at the local amino acid level, the local flexibility found outside disulfide bond regions may be required to localize the antibody sequence to be cleaved within the enzyme bag. Interestingly, this conclusion is supported by comparisons of digestion efficiencies under different pH, heat, and organic conditions. Although different efficiencies were observed, the cleavage sites were found to be consistent across the conditions. Despite possible denaturation at the secondary structure level, the treatments left the disulfide bond pattern unaffected, suggesting that this restriction is a major factor in determining the cleavage site. When digestion extends to the bispecific antibody, CH2 / CH3 digestion in the anti-CD3 arm is prevented from extending beyond the hinge region, contrary to the standard IgG1 cathepsin L+D digestion pattern observed in the anti-Her2 arm. The anti-Her2 cleavage occurs at a location with homologous primary and secondary sequences to the anti-CD3 arm, suggesting the role of sequence local flexibility, domain orientation, or other tertiary (pore) effects in determining cathepsin L and D digestion.
[0147] Comparison of protein fragments identified in trastuzumab under standard conditions (pH 7, 37°C, 2 days, 1:20 ratio) versus optimized conditions revealed interesting differences in their relative abundance (Tables 8-10). For example, the most abundant low molecular weight peptide at pH 7 was a 11,197 Da (HC: 1-102 (YYCSRWGGD.F)) fragment, while at the optimal pH 4, the most abundant fragment below 20 kDa was a 12,121 Da (LC: 1-110 (RTVA.A)) product. One possibility is that cathepsins L and D influence each other's activity when combined in a pool, either by cleaving the other enzyme or via stoichiometric effects when bound to the Ab. No intact mass of cathepsins L or D was observed during deconvolution; however, some observed masses of ≈25 kDa may correspond to small cleaved fragments of cathepsin L (30 kDa) or highly cleaved forms of cathepsin D (≈45 kDa). This could explain some unidentified material during deconvolution in the cleavage assessment.
[0148] The cleavage patterns observed with cathepsins L and D suggest that cathepsin treatment can also be used as a relatively simple detection method for examining disulfide bonds in Abs. Both cathepsins may produce a “single-arm” fragment of approximately 48 kDa for IgG1, but not for IgG2-B Abs containing a unique disulfide bond pattern. The IgG2-B pattern is difficult to examine by non-reducing peptide mapping and is most commonly examined by Lys-C [66,67].
[0149] Here, we use high-resolution native MS and denaturing LC-MS in parallel on directly injected non-reducing Abs. This method is simple, requires minimal sample preparation, and features mild source conditions with minimal or no passive intracellular cleavage. Disulfide bond reduction and deglycosylation improve sensitivity and simplify mass spectrometry and data analysis, but add additional steps to the proposed method. Using software capable of automating complete dispensing helps accelerate the evaluation of novel proteases and holds promise as a computational resource for evaluating natural splicing within cells or antibody byproducts. This method produces protein fragments of ideal size for sequencing, achieves 100% Ab coverage across a limited number of protein fragments (nine substances), and uses commercially available enzymes, making this workflow suitable as a robust and reproducible mid-to-bottom sequencing workflow.
[0150] C. Method
[0151] C.1. Chemicals and Materials
[0152] Therapeutic Ab rituximab Obin eutozumab and ikuzumab It was a free gift from Genmab (The Netherlands), and trastuzumab... The anti-Her2 / anti-CD3 bispecific antibody was supplied in-house by Genentech. Except for the bispecific antibody, all Ab samples were from expired batches. Ab integrity was checked by native MS prior to use to ensure no post-translational modifications or structural changes had occurred (checked by charge state distribution), and that the Abs were expected to have high integrity. All searched amino acid sequences lacked the N-terminal signal peptide and are provided in Table 14. Dithiothreitol (DTT), iodoacetamide (IAA), ammonium acetate (AMAC), acetic acid, formic acid (FA), 8M hydroxymethyl aminomethane (Tris), methanol (MeOH), and cathepsins L and D were purchased from Sigma-Aldrich (St. Louis, MO); phosphate buffer was from Lonza Group AG (Basel, CH). Acetonitrile (ACN) was purchased from Biosolve BV (North Brabant, NL) and Fisher Scientific (Hampton, NH).
[0153] C.2. Antibody digestion of cathepsin L and cathepsin D
[0154] To evaluate suitable Ab motifs for cleavage by cathepsins L and D, all therapeutic Abs (rituximab, olibutuzumab, eculizumab, trastuzumab) were digested under single control conditions. Abs were prepared in Milli-Q water at a concentration of 5 μM and treated with cathepsins L or D at an enzyme to antibody ratio of 1:200. Samples were incubated at 37°C at neutral pH for 2 days. The digested Ab sample buffer was exchanged to 150 mM AMAC aqueous solution (pH 7.5) by centrifugation using a 10 kDa cutoff filter (Merck Millipore, Burlington, MA). The final protein concentration was measured by UV absorbance at 280 nm. The digestion buffer was adjusted to 2–3 μM and used directly for native MS analysis, or incubated overnight with 4 units of PNGase F using the standard native digestion protocol
[22] . The PNGase F-treated sample buffer was exchanged again to 150 mM AMAC (pH 7.5) before native MS measurement.
[0155] Next, the cleavage efficiency of each cathepsin under different digestion conditions was explored using a single Ab (trastuzumab) at a stock solution of 2 mg / mL. Each cathepsin was resuspended in water at 1 mg / mL, and tests were performed in triplicate under different pH, MeOH, and temperature conditions (Table 15). Digestants were prepared at a 1:200 enzyme-to-protein ratio, resulting in a final Ab concentration of 0.2 mg / mL. For pH-adjusted formulations, 50 mM ammonium acetate dilution buffer was added to 79% of the solution to achieve the desired pH. For LC-UV-MS analysis, 15 μL was injected into the DAD detector (254 nm) and Exactive... TM EMR (Thermo Fisher Scientific, Waltham, MA) connected to the Ultimate 3000LC with a 2.1×50mm MAbPac TM RP HPLC column (80℃). Flow rate set at 300 μL / min, with mobile phase A (MPA) consisting of 99.88% water, 0.1% formic acid, and 0.02% trifluoroacetic acid, and mobile phase B (MPB) consisting of 90% ACN, 9.88% water, 0.02% trifluoroacetic acid, and 0.1% formic acid. MPB increased from 5% to 20% at 1 minute, to 65% at 9.5 minutes, and to 90% at 10 minutes, and remained at 90% for 2 minutes before reequilibration.
[0156] The final one-pot reaction for evaluating L+D in trastuzumab was performed at pH 4.0 and 37°C for 18 hours. As described above, LC-UV-MS was used to assess complete quality. Samples directly buffer-exchanged to 50 mM ammonium acetate were subjected to Q-Exactive chromatography using a Micro Bio-Spin column according to the manufacturer's instructions. TM Top-down analysis of UHMR. These settings were adjusted as described in the Static nESI MS section below.
[0157] C.3. Static nESI MS of cathepsin L and D fragments
[0158] In the improved Exactive with extended quality range (EMR) TM Plus Orbitrap instrument (ThermoFisher Scientific)
[68] or Q Exactive using a range of 500–12,000 m / z. TM Samples were analyzed on UHMR
[69] . The voltage offset on the transport multipole and ion lens was manually adjusted to achieve optimal transport of protein ions at elevated m / z. Nitrogen gas was applied at 3-7 × 10⁻⁶ m / z. -10The high-energy collisional dissociation (HCD) cell was used at a pressure of 8 bar. The MS parameters used were: spray voltage 1.2–1.3 V, source temperature 250 °C, source dissociation and collision energies varied between 50–80 V, and the resolution of all Abs (at m / z 200) was 35,000 or 70,000. As previously mentioned, the instrument was mass-calibrated using CsI solution
[22] .
[0159] C.3. Adamantium degradation
[0160] Antibody cleavage by cathepsins from a pot of trastuzumab L+D digestion at 4-20% Novex TM Tris-glycine was separated on a Tris-glycine SDS-PAGE gel (Thermo Fisher Scientific) and electroblotted onto a PVDF membrane, followed by staining with Coomassie Brilliant Blue R-250 for visualization. 494 Procise was used. TM The sequencer (Applied Biosystems, Foster City, CA) was used to remove the band of interest and perform N-terminal sequence analysis. The resulting sequence mixture was analyzed and manually verified using the sequencer's 610 software (Applied Biosystems, Foster City, CA).
[0161] C.4. Analysis of Antibody Digestion Product Data
[0162] Intact Mass TM Version 3.2-424 (October 2018) is used for charge deconvolution (Protein Metrics, SanCarlos, CA). For initial deconvolution, preset parameters are used, including m / z range 600–9,000, m range 10,000–160,000, m / z spacing 0.04, m / z smoothing σ 0.02, 0.2 charge spacing, m spacing 0.5, and m smoothing σ 3.0. For subsequent deconvolution, the parameters are adjusted to produce the highest quality results. In all cases, the minimum difference between quality peaks is 15, resulting in a peak detector σ of 5 (one-third of the minimum difference between quality peaks). A 4 Da quality matching tolerance is used for automatic peak annotation.
[0163] Therefore, this outlines the Intact Mass commercial releases of 2019. TMThe details of the program, specifically the matching algorithm for sheared substances, have not been described in the scientific literature. After charge deconvolution [27,59], the algorithm uses a "Mexican hat" peak detection filter to select peaks in the medium mass spectrum in descending order of intensity, while prioritizing the mass found at the shoulder of the peak cluster. Customizable settings are available for specifying the peak detector width (standard deviation of the positive portion of the filter, default = 5 Da), mass range, maximum number, minimum mass spacing, minimum percentage of the base peak, and minimum signal-to-noise ratio for peak selection.
[0164] The deconvolution and selected peaks were matched with the theoretical average isotopic mass calculated based on the input amino acid sequence (including multiple chains) and the natural isotopic abundance table. Characteristics of the biological source were specified. 13 C abundance (1.079%). The average mass is used to avoid the difference in Dalton error in the mass of a single isotope and to provide homogeneity on mass spectra of mixtures that may contain both resolved and unresolved masses of isotopes.
[0165] Each peptide bond in either the light or heavy chain is considered a potential cleavage site, rather than restricting cleavage to preferred amino acids. In the matching algorithm, suffixes beginning with Q (sequences containing the C-terminus of the chain but not the N-terminus) are not assumed to begin with pyro-Glu, while prefixes (sequences containing the N-terminus of the chain but not the C-terminus) are assumed to do so. By default, C (cysteine) is assumed to be disulfide-bonded, single odd Cs are still reduced, and the whole mass is subtracted by about 1 Da without attempting a predicted pattern. This algorithm is a simple greedy algorithm
[70] : each selected peak is matched with the closest theoretical mass within the set mass tolerance. Except in the special case of cleaving the same chain at the same position, the whole mass is calculated by cleaving only a single chain and adding it to another whole second chain. For a whole mAb, two LCs and two HCs are tandemly linked so that the Intact Mass will produce the prefix and suffix by cleaving a single chain while keeping the other three chains intact. The software will also consider two identical strands cleaved at the same location, such as the F(ab')2 fragment produced by cleavage between the Gs in CPCCPPAPELLG.GPS by the IdeS protease. It will automatically consider the cleavage of "half-Abs" formed by a single LC+HC.
[0166] All assignments were manually verified, and all unassigned substances were manually evaluated to determine if the algorithm had missed any assignments.
[0167] D. References
[0168] 1.Vandermarliere,E.,Stes,E.,Gevaert,K.&Martens,L.(2016)Resolution ofprotein structure by mass spectrometry,Mass Spectrom Rev.35,653-665.
[0169] 2.Rathore,D.,Faustino,A.,Schiel,J.,Pang,E.,Boyne,M.&Rogstad,S.(2018)The role of mass spectrometry in the characterization of biologic proteinproducts,Expert Review of Proteomics.15,431-449.
[0170] 3.Muth,T.,Hartkopf,F.,Vaudel,M.&Renard,B.Y.(2018)A Potential GoldenAge to Come—Current Tools,Recent Use Cases,and Future Avenues for De NovoSequencing in Proteomics,Proteomics.18,1700150.
[0171] 4.Standing,K.G.(2003)Peptide and protein de novo sequencing by massspectrometry,Curr Opin Struct Biol.13,595-601.
[0172] 5.(1999)De Novo Peptide Sequencing via Tandem Mass Spectrometry,JComput Biol.6,327-342.
[0173] 6.Ma,B.,Zhang,K.,Hendrie,C.,Liang,C.,Li,M.,Doherty-Kirby,A.&Lajoie,G.(2003)PEAKS:powerful software for peptide de novo sequencing by tandem massspectrometry,Rapid Commun Mass Spectrom.17,2337-2342.
[0174] 7.Seidler,J.,Zinn,N.,Boehm,M.E.&Lehmann,W.D.(2010)De novo sequencingof peptides by MS / MS,Proteomics.10,634-649.
[0175] 8.Liu,P.,Zhu,X.,Wu,W.,Ludwig,R.,Song,H.,Li,R.,Zhou,J.,Tao,L.&Leone,A.M.(2019)Subunit mass analysis for monitoring multiple attributes ofmonoclonal antibodies,Rapid Commun Mass Spectrom.33,31-40.
[0176] 9. K.,Nagornov,K.O.,Fornelli,L.,Lobas,A.A.,Ayoub,D.,Kozhinov,A.N.,Gasilova,N.,Menin,L.,Beck,A.,Gorshkov,M.V.,Aizikov,K.&Tsybin,Y.O.(2018)Multiplexed Middle-Down Mass Spectrometry as a Method for Revealing Light andHeavy Chain Connectivity in a Monoclonal Antibody,Anal Chem.90,12527-12535.
[0177] 10.Pandeswari,P.B.&Sabareesh,V.(2019)Middle-down approach:a choice tosequence and characterize proteins / proteomes by mass spectrometry,RSCAdvances.9,313-344.
[0178] 11.Tsiatsiani,L.&Heck,A.J.R.(2015)Proteomics beyond trypsin,The FEBSJournal.282,2612-2626.
[0179] 12.Vincents,B.,von Pawel-Rammingen,U., L.&Abrahamson,M.(2004)Enzymatic Characterization of the Streptococcal Endopeptidase,IdeS,RevealsThat It Is a Cysteine Protease with Strict Specificity for IgG Cleavage Dueto Exosite Binding,Biochemistry.43,15540-15549.
[0180] 13.von Pawel-Rammingen,U.,Johansson,B.P.& L.(2002)IdeS,a novelstreptococcal cysteine proteinase with unique specificity for immunoglobulinG,The EMBO journal.21,1607-1615.
[0181] 14.Fornelli,L.,Ayoub,D.,Aizikov,K.,Liu,X.,Damoc,E.,Pevzner,P.A.,Makarov,A.,Beck,A.&Tsybin,Y.O.(2017)Top-down analysis of immunoglobulin Gisotypes 1 and 2 with electron transfer dissociation on a high-field Orbitrapmass spectrometer,J Proteomics.159,67-76.
[0182] 15. K.,Zhurov,K.O.,Lobas,A.A.,Nikitin,G.,Fornelli,L.,Gorshkov,M.V.&Tsybin,Y.O.(2018)Chemical-Mediated Digestion:An Alternative Realm forMiddle-down Proteomics?,J Proteome Res.17,2005-2016.
[0183] 16.McCool,E.N.,Chen,D.,Li,W.,Liu,Y.&Sun,L.(2019)Capillary zoneelectrophoresis-tandem mass spectrometry with ultraviolet photodissociation(213 nm)for large-scale top–down proteomics,Analytical Methods.11,2855-2861.
[0184] 17.Cannon,J.R.,Cammarata,M.B.,Robotham,S.A.,Cotham,V.C.,Shaw,J.B.,Fellers,R.T.,Early,B.P.,Thomas,P.M.,Kelleher,N.L.&Brodbelt,J.S.(2014)Ultraviolet photodissociation for characterization of whole proteins on achromatographic time scale,Anal Chem.86,2185-2192.
[0185] 18.Shaw,J.B.,Malhan,N.,Vasil’ev,Y.V.,Lopez,N.I.,Makarov,A.,Beckman,J.S.&Voinov,V.G.(2018)Sequencing Grade Tandem Mass Spectrometry for Top–DownProteomics Using Hybrid Electron Capture Dissociation Methods in a BenchtopOrbitrap Mass Spectrometer,Anal Chem.90,10819-10827.
[0186] 19.Shaw,J.B.,Li,W.,Holden,D.D.,Zhang,Y.,Griep-Raming,J.,Fellers,R.T.,Early,B.P.,Thomas,P.M.,Kelleher,N.L.&Brodbelt,J.S.(2013)Complete proteincharacterization using top-down mass spectrometry and ultravioletphotodissociation,J Am Chem Soc.135,12646-12651.
[0187] 20.Catherman,A.D.,Skinner,O.S.&Kelleher,N.L.(2014)Top Downproteomics:facts and perspectives,Biochem Biophys Res Commun.445,683-693.
[0188] 21.Tran,J.C.,Zamdborg,L.,Ahlf,D.R.,Lee,J.E.,Catherman,A.D.,Durbin,K.R.,Tipton,J.D.,Vellaichamy,A.,Kellie,J.F.,Li,M.,Wu,C.,Sweet,S.M.M.,Early,B.P.,Siuti,N.,LeDuc,R.D.,Compton,P.D.,Thomas,P.M.&Kelleher,N.L.(2011)Mappingintact protein isoforms in discovery mode using top-down proteomics,Nature.480,254-258.
[0189] 22.Rosati,S.,Yang,Y.,Barendregt,A.&Heck,A.J.R.(2014)Detailed massanalysis of structural heterogeneity in monoclonal antibodies using nativemass spectrometry,Nat Protoc.9,967-976.
[0190] 23.Bailey,A.O.,Han,G.,Phung,W.,Gazis,P.,Sutton,J.,Josephs,J.L.&Sandoval,W.(2018)Charge variant native mass spectrometry benefits massprecision and dynamic range of monoclonal antibody intact mass analysis,Mabs-Austin.10,1214-1225.
[0191] 24.Phung,W.,Han,G.,Polderdijk,S.G.I.,Dillon,M.,Shatz,W.,Liu,P.,Wei,B.,Suresh,P.,Fischer,D.,Spiess,C.,Bailey,A.,Carter,P.J.,Lill,J.R.&Sandoval,W.(2019)Characterization of bispecific and mispaired IgGs by native charge-variant mass spectrometry,Int J Mass spectrom.446,116229。
[0192] 25. T.,Tian,W.,Yang,Z.,Clausen,H.&Heck,A.J.R.(2018)Directquality control of glycoengineered erythropoietin variants,Nat Commun.9,3342.
[0193] 26.Wohlschlager,T.,Scheffler,K.,Forstenlehner,I.C.,Skala,W.,Senn,S.,Damoc,E.,Holzmann,J.&Huber,C.G.(2018)Native mass spectrometry combined withenzymatic dissection unravels glycoform heterogeneity of biopharmaceuticals,Nat Commun.9,1713.
[0194] 27.Campuzano,I.D.G.,Robinson,J.H.,Hui,J.O.,Shi,S.D.H.,Netirojjanakul,C.,Nshanian,M.,Egea,P.F.,Lippens,J.L.,Bagal,D.,Loo,J.A.&Bern,M.(2019)Nativeand Denaturing MS Protein Deconvolution for Biopharma:Monoclonal Antibodiesand Antibody–Drug Conjugates to Polydisperse Membrane Proteins and Beyond,Anal Chem.91,9472-9480.
[0195] 28.Marcoux,J.,Wang,S.C.,Politis,A.,Reading,E.,Ma,J.,Biggin,P.C.,Zhou,M.,Tao,H.,Zhang,Q.,Chang,G.,Morgner,N.&Robinson,C.V.(2013)Mass spectrometryreveals synergistic effects of nucleotides,lipids,and drugs binding to amultidrug resistance efflux pump,P Natl Acad Sci USA.110,9704-9709.
[0196] 29.Yang,Y.,Liu,F.,Franc,V.,Halim,L.A.,Schellekens,H.&Heck,A.J.R.(2016)Hybrid mass spectrometry approaches in glycoprotein analysis and theirusage in scoring biosimilarity,Nat Commun.7,13397.
[0197] 30.Greisch,J.-F.,Tamara,S.,Scheltema,R.A.,Maxwell,H.W.R.,Fagerlund,R.D.,Fineran,P.C.,Tetter,S.,Hilvert,D.&Heck,A.J.R.(2019)Expanding the massrange for UVPD-based native top-down mass spectrometry,Chemical Science.10,7163-7171.
[0198] 31.Compton,P.D.,Zamdborg,L.,Thomas,P.M.&Kelleher,N.L.(2011)On thescalability and requirements of whole protein mass spectrometry,Anal Chem.83,6868-6874.
[0199] 32.McLuckey,S.A.&Stephenson,J.L.(1998)Ion / ion chemistry of high-massmultiply charged ions,Mass Spectrom Rev.17,369-407.
[0200] 33.Ge,Y.,Lawhorn,B.G.,ElNaggar,M.,Strauss,E.,Park,J.-H.,Begley,T.P.&McLafferty,F.W.(2002)Top Down Characterization of Larger Proteins(45 kDa)byElectron Capture Dissociation Mass Spectrometry,J Am Chem Soc.124,672-678.
[0201] 34.Reid,G.E.,Wu,J.,Chrisman,P.A.,Wells,J.M.&McLuckey,S.A.(2001)Charge-State-Dependent Sequence Analysis of Protonated Ubiquitin Ions via IonTrap Tandem Mass Spectrometry,Anal Chem.73,3274-3281.
[0202] 35.Zhang,H.,Cui,W.,Wen,J.,Blankenship,R.E.&Gross,M.L.(2011)NativeElectrospray and Electron-Capture Dissociation FTICR Mass Spectrometry forTop-Down Studies of Protein Assemblies,Anal Chem.83,5598-5606.
[0203] 36.Syka,J.E.P.,Coon,J.J.,Schroeder,M.J.,Shabanowitz,J.&Hunt,D.F.(2004)Peptide and protein sequence analysis by electron transfer dissociationmass spectrometry,P Natl Acad Sci USA.101,9528-9533.
[0204] 37.Moelleken,J.,Endesfelder,M.,Gassner,C.,Lingke,S.,Tomaschek,S.,Tyshchuk,O.,Lorenz,S.,Reiff,U.& M.(2017)GingisKHAN TMprotease cleavageallows a high-throughput antibody to Fab conversion enabling directfunctional assessment during lead identification of human monoclonal andbispecific IgG1 antibodies,Mabs-Austin.9,1076-1087.
[0205] 38.Zhang,L.,English,A.M.,Bai,D.L.,Ugrin,S.A.,Shabanowitz,J.,Ross,M.M.,Hunt,D.F.&Wang,W.-H.(2016)Analysis of Monoclonal Antibody Sequence andPost-translational Modifications by Time-controlled Proteolysis and TandemMass Spectrometry,Molecular&cellular proteomics:MCP.15,1479-1488.
[0206] 39.Mao,Y.,Zhang,L.,Kleinberg,A.,Xia,Q.,Daly,T.J.&Li,N.(2019)Fastprotein sequencing of monoclonal antibody by real-time digestion on emitterduring nanoelectrospray,Mabs-Austin.11,767-778.
[0207] 40.Jones,R.G.A.&Landon,J.(2002)Enhanced pepsin digestion:a novelprocess for purifying antibody F(ab′)2 fragments in high yield from serum,JImmunol Methods.263,57-74.
[0208] 41.Wu,C.,Tran,J.C.,Zamdborg,L.,Durbin,K.R.,Li,M.,Ahlf,D.R.,Early,B.P.,Thomas,P.M.,Sweedler,J.V.&Kelleher,N.L.(2012)A protease for'middle-down'proteomics,Nat Methods.9,822-824.
[0209] 42. K.,Fornelli,L.,Laskay, A.,Monod,M.,Beck,A.,Ayoub,D.&Tsybin,Y.O.(2014)Advantages of Extended Bottom-Up Proteomics Using Sap9 forAnalysis of Monoclonal Antibodies,Anal Chem.86,9945-9953.
[0210] 43.Smith,S.M.&Gottesman,M.M.(1989)Activity and deletion analysis ofrecombinant human cathepsin L expressed in Escherichia coli,J Biol Chem.264,20487-95.
[0211] 44.Kirschke,H.,Kembhavi,A.A.,Bohley,P.&Barrett,A.J.(1982)Action ofrat liver cathepsin L on collagen and other substrates,The Biochemicaljournal.201,367-372.
[0212] 45.Press,E.M.,Porter,R.R.&Cebra,J.(1960)The isolation and propertiesof a proteolytic enzyme,cathepsin D,from bovine spleen,The Biochemicaljournal.74,501-514.
[0213] 46.Brix,K.(2005)Lysosomal Proteases:Revival of the Sleeping Beauty.inMadame Curie Bioscience Database(Saftig,P.,ed),Landes Bioscience,Austin(TX).
[0214] 47.Dunn,A.D.,Crutchfield,H.E.&Dunn,J.T.(1991)Thyroglobulin processingby thyroidal proteases.Major sites of cleavage by cathepsins B,D,and L,J BiolChem.266,20198-204.
[0215] 48.Biniossek,M.L., D.K.,Becker-Pauly,C.&Schilling,O.(2011)Proteomic Identification of Protease Cleavage Sites Characterizes Prime andNon-prime Specificity of Cysteine Cathepsins B,L,and S,J Proteome Res.10,5363-5373.
[0216] 49.Gosalia,D.N.,Salisbury,C.M.,Ellman,J.A.&Diamond,S.L.(2005)HighThroughput Substrate Specificity Profiling of Serine and Cysteine ProteasesUsing Solution-phase Fluorogenic Peptide Microarrays,Molecular&;CellularProteomics.4,626-636.
[0217] 50.Puzer,L.,Cotrin,S.S.,Alves,M.F.M.,Egborge,T.,Ara ú jo,M.S.,Juliano,M.A.,Juliano,L., D.&Carmona,A.K.(2004)Comparative substratespecificity analysis of recombinant human cathepsin V and cathepsin L,ArchBiochem Biophys.430,274-283.
[0218] 51.Hu,Y.,Morioka,K.&Itoh,Y.(2007)Existence of Cathepsin L and itsChracterization in Red Bulleye Surimi.,Pakistan Journal of BiologicalSciences.10,78-83.
[0219] 52.Luo,H.B.,Tie,L.,Cao,M.Y.,Hunter,A.K.,Pabst,T.M.,Du,J.L.,Field,R.,Li,Y.L.&Wang,W.K.(2019)Cathepsin L Causes Proteolytic Cleavage of Chinese-Hamster-Ovary Cell Expressed Proteins During Processing and Storage:Identification,Characterization,and Mitigation,Biotechnol Progr.35.
[0220] 53.Tang,J.&Wong,R.N.S.(1987)Evolution in the structure and functionof aspartic proteases,J Cell Biochem.33,53-63.
[0221] 54.Sun,H.,Lou,X.,Shan,Q.,Zhang,J.,Zhu,X.,Zhang,J.,Wang,Y.,Xie,Y.,Xu,N.&Liu,S.(2013)Proteolytic Characteristics of Cathepsin D Related to theRecognition and Cleavage of Its Target Proteins,PLOS ONE.8,e65733.
[0222] 55.van Noort,J.M.&van der Drift,A.C.(1989)The selectivity ofcathepsin D suggests an involvement of the enzyme in the generation of T-cellepitopes,J Biol Chem.264,14159-14164.
[0223] 56.Woessner Jr.,J.(1977)Specificity and biological role of cathepsinD.,Adv Exp Med Biol.95,313-327.
[0224] 57.Bee,J.S.,Tie,L.,Johnson,D.,Dimitrova,M.N.,Jusino,K.C.&Afdahl,C.D.(2015)Trace levels of the CHO host cell protease cathepsin D caused particleformation in a monoclonal antibody product,Biotechnol Progr.31,1360-1369.
[0225] 58.Zhang,Z.,Pan,H.&Chen,X.(2009)Mass spectrometry for structuralcharacterization of therapeutic antibodies,Mass Spectrom Rev.28,147-176.
[0226] 59.Bern,M.,Caval,T.,Kil,Y.J.,Tang,W.,Becker,C.,Carlson,E.,Kletter,D.,Sen,K.I.,Galy,N.,Hagemans,D.,Franc,V.&Heck,A.J.R.(2018)Parsimonious ChargeDeconvolution for Native Mass Spectrometry,J Proteome Res.17,1216-1226.
[0227] 60.Terra,W.R.,Dias,R.O.&Ferreira,C.(2019)Recruited lysosomal enzymesas major digestive enzymes in insects,Biochem Soc Trans.47,615-623.
[0228] 61.Honey,K.&Rudensky,A.Y.(2003)Lysosomal cysteine proteases regulateantigen presentation,Nature Reviews Immunology.3,472-482.
[0229] 62.Fellers,R.T.,Greer,J.B.,Early,B.P.,Yu,X.,LeDuc,R.D.,Kelleher,N.L.&Thomas,P.M.(2015)ProSight Lite:graphical software to analyze top-down massspectrometry data,Proteomics.15,1235-1238.
[0230] 63.Merchant,A.M.,Zhu,Z.,Yuan,J.Q.,Goddard,A.,Adams,C.W.,Presta,L.G.&Carter,P.(1998)An efficient route to human bispecific IgG,Nat Biotechnol.16,677-681.
[0231] 64.van der Laarse,S.A.M.,van Gelder,C.A.G.H.,Bern,M.,Akeroyd,M.,Olsthoorn,M.M.A.&Heck,A.J.R.Targeting proline in(phospho)proteomics,The FEBSJournal.n / a.
[0232] 65.Isenman,D.E.,Dorrington,K.J.&Painter,R.H.(1975)The Structure andFunction of Immunoglobulin Domains,II The Importance of Interchain DisulfideBonds and the Possible Role of Molecular Flexibility in the InteractionBetween Immunoglobulin G and Complement.114,1726-1729.
[0233] 66.Wypych,J.,Li,M.,Guo,A.,Zhang,Z.,Martinez,T.,Allen,M.J.,Fodor,S.,Kelner,D.N.,Flynn,G.C.,Liu,Y.D.,Bondarenko,P.V.,Ricci,M.S.,Dillon,T.M.&Balland,A.(2008)Human IgG2 antibodies display disulfide-mediated structuralisoforms,The Journal of biological chemistry.283,16194-16205.
[0234] 67.Resemann,A.,Liu-Shin,L.,Tremintin,G.,Malhotra,A.,Fung,A.,Wang,F.,Ratnaswamy,G.&Suckau,D.(2018)Rapid,automated characterization of disulfidebond scrambling and IgG2 isoform determination,Mabs-Austin.10,1200-1213.
[0235] 68.Rose,R.J.,Damoc,E.,Denisov,E.,Makarov,A.&Heck,A.J.R.(2012)High-sensitivity Orbitrap mass analysis of intact macromolecular assemblies,NatMethods.9,1084-1086.
[0236] 69. van de Waterbeemd, M., Fort, KL, Boll, D., Reinhardt-Szyba, M., Routh, A., Makarov, A. & Heck, AJR (2017) High-fidelity mass analysis unveilsheterogeneity in intact ribosomal particles, Nat Methods.14, 283-286.
[0237] 70. Temlyakov, V. (2008) Greedy Approximation in Acta Numerica (Iserles, A., ed) pp. 235-409, Cambridge University Press, Cambridge, England.
[0238] 71. Thomsen, MCF & Nielsen, M. (2012) Seq2Logo: a method for construction and visualization of amino acid binding motifs and sequence profiles including sequence weighting, pseudo counts and two-sided representation of amino acid enrichment and depletion, Nucleic Acids Res. 40, W281-W287.
[0239] E. Table
[0240] Table 1. Conditions for testing cathepsin D / L activity at a 1:20 mAb:enzyme ratio.
[0241]
[0242] Table 2. Rituximab exposed to cathepsin L. a
[0243]
[0244]
[0245] a Cut-off sites are indicated by AA sequence numbers and ".". Unallocated sites are indicated by "ND".
[0246] Table 3. Rituximab exposed to cathepsin D. a
[0247]
[0248] a Cut-off sites are indicated by AA sequence numbers and ".". Unallocated sites are indicated by "ND".
[0249] Table 4. Protein fragments from cathepsin L and D digestion by bispecific IgG1 cathepsin. When the anti-Her2 and anti-CD3 chains are perfectly homologous, the protein fragments are listed in the "Nonspecific" section. For fragments corresponding to unique sequences, the associated chains are listed.
[0250]
[0251]
[0252]
[0253] Table 5a. Distribution of Obinutuzumab cathepsin L digests. Obinutuzumab exposed to cathepsin L produces a complete sequence involving a cleavage in CDR H3, a cleavage at the end of the HC variable portion, and a cleavage in the heavy chain hinge region. All heavy chain sequences of oxetuzumab begin with the N-terminus pyro-Glu, not Glu.
[0254] quality Expected quality strength distribute 10866.33 10867.06 8.80E+04 HC 1-99(…AVYYCARN.V) 14681.96 14682.36 4.55E+04 HC 1-135(…FPLAPSSK.S) 14869.87 14870.55 3.02E+04 HC 1-137(…LAPSSKST.S) 14957.54 14957.62 2.73E+04 HC 1-138(…APSSKSTS.G) 15014.36 15014.68 6.57E+04 HC 1-139(…PSSKSTSG.G) 22544.58 22545.16 2.27E+04 LC 1-206(…CEVTHQGL.S) 23491.56 23492.22 2.59E+04 HC 1-220(…VDKKVEPK.S) 23834.75 23835.55 9.00E+04 LC 1-218(…TKSFNRGE.C) 23904.34 4.75E+04 ND 23938.56 23938.69 3.96E+04 LC 24057.36 23957.83 2.82E+05 LC+ cysteamine acylation 24243.96 4.77E+04 ND 47618.71 47619.12 1.81E+06 LC+HC: 1-222(…KKVEPKSC.D) 47734.36 47734.21 8.32E+05 LC+HC: 1-223(…KVEPKSCD.K) 47861.76 47862.38 1.92E+06 LC+HC: 1-224(…VEPKSCDK.T) 47962.73 47963.49 7.09E+05 LC+HC: 1-225(…EPKSCDKT.H) 48099.86 48100.63 5.31E+06 LC+HC: 1-226(…PKSCDKTH.T) 48201.09 48201.73 1.00E+06 LC+HC: 1-227(…KSCDKTHT.C)
[0255] Table 5b. Distribution of Obinutuzumab cathepsin D digests. Obinutuzumab exposed to cathepsin D produces a series of cleavages in the heavy chain hinge region, as well as cleavage of the heavy chain that separates F(ab')2 from Fc.
[0256]
[0257]
[0258] Table 6. Distribution of eculizumab cathepsin L by digestion. Eculizumab exposed to cathepsin L undergoes cleavage in CDRH3. Unlike IgG1 mAb, eculizumab does not exhibit heavy chain cleavage that breaks down individual antibody arms, suggesting that eculizumab possesses the IgG2-B disulfide bond pattern shown in Figure 3.
[0259] quality Expected quality strength distribute 11437.82 11438.74 1.28E+05 HC: 1-102(...YCARYFFG.S) 11524.84 11525.82 1.10E+05 HC: 1-103(...CARYFFGS.S) 11823.08 11824.12 4.96E+05 HC: 1-106(...YFFGSSPN.W) 11838.69 2.93E+05 ND 11854.45 1.38E+05 ND
[0260] Table 7. Distribution of eculizumab cathepsin D digests. Cathepsin D cleaves eculizumab in CDR H3 and cleaves F(ab')2 from Fc.
[0261]
[0262]
[0263] Table 8. Distribution of trastuzumab cathepsin L digests in samples at pH 7, 37℃, 2 days, and a 1:20 dilution. QExactive TM The analysis was performed on EMR using LC-MS.
[0264]
[0265] Table 9. Distribution of trastuzumab cathepsin D digests in samples at pH 7, 37℃, 2 days, and a 1:20 dilution. QExactive TM The analysis was performed on EMR using LC-MS.
[0266]
[0267]
[0268] Table 10. Peptides derived from optimized trastuzumab digestion. a
[0269]
[0270] a Allocations were performed using a combination of antibody-specific rules (e.g., excluding sequences containing NST if the glycoform is absent) and precise mass. For substances <50 kDa, all allocations were performed within 2 Da, and for substances <100 kDa, all allocations were performed within 4 Da.
[0271] Table 11. Unconvolution quality of trastuzumab cathepsin samples from optimized samples. The following data will not be searched for sequence matches unless they are found in Table 5a.
[0272]
[0273]
[0274] Table 12. Top-down analysis of 12.12 kDa peptides. The product ions and their associated errors are listed (all within 10 ppm).
[0275]
[0276]
[0277]
[0278]
[0279]
[0280]
[0281]
[0282]
[0283]
[0284]
[0285]
[0286]
[0287] Table 14. Amino acid sequences of the monoclonal antibodies and enzymes used in the study.
[0288]
[0289]
[0290]
[0291] Table 15. Conditions for testing cathepsin D / L activity at a 1:200 mAb:enzyme ratio (wt:wt)
[0292] sequence list <110> Genentech, Inc. Utrecht University Holding Company SANDOVAL, Wendy, et al. <120> Methods for mid-to-bottom antibody characterization <130> 01164-0008-00PCT <140> PCT / US2021 / 042164 <141> 2021-07-19 <150> US 63 / 053,899 <151> 2020-07-20 <160> 183 <170> PatentIn version 3.5 <210> 1 <211> 213 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 1 Gln Ile Val Leu Ser Gln Ser Pro Ala Ile Leu Ser Ala Ser Pro Gly 1 5 10 15 Glu Lys Val Thr Met Thr Cys Arg Ala Ser Ser Ser Val Ser Tyr Ile 20 25 30 His Trp Phe Gln Gln Lys Pro Gly Ser Ser Pro Lys Pro Trp Ile Tyr 35 40 45 Ala Thr Ser Asn Leu Ala Ser Gly Val Pro Val Arg Phe Ser Gly Ser 50 55 60 Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Arg Val Glu Ala Glu 65 70 75 80 Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Thr Ser Asn Pro Pro Thr 85 90 95 Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala Pro 100 105 110 Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr 115 120 125 Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys 130 135 140 Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu 145 150 155 160 Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser 165 170 175 Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala 180 185 190 Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe 195 200 205 Asn Arg Gly Glu Cys 210 <210> 2 <211> 451 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 2 Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Asn Met His Trp Val Lys Gln Thr Pro Gly Arg Gly Leu Glu Trp Ile 35 40 45 Gly Ala Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr Asn Gln Lys Phe 50 55 60 Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Ser Thr Tyr Tyr Gly Gly Asp Trp Tyr Phe Asn Val Trp Gly 100 105 110 Ala Gly Thr Thr Val Thr Val Ser Ala Ala Ser Thr Lys Gly Pro Ser 115 120 125 Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala 130 135 140 Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val 145 150 155 160 Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala 165 170 175 Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val 180 185 190 Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His 195 200 205 Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Ala Glu Pro Lys Ser Cys 210 215 220 Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 225 230 235 240 Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 245 250 255 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 260 265 270 Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 275 280 285 His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr 290 295 300 Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 305 310 315 320 Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 325 330 335 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 340 345 350 Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser 355 360 365 Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 370 375 380 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 385 390 395 400 Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 405 410 415 Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 420 425 430 His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 435 440 445 Pro Gly Light 450 <210> 3 <211> 219 <212> PRT <213> artificial sequence <220> <223> synthetic <400> 3 Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Thr Pro Gly 1 5 10 15 Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Lys Ser Leu Leu His Ser 20 25 30 Asn Gly Ile Thr Tyr Leu Tyr Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35 40 45 Pro Gln Leu Leu Ile Tyr Gln Met Ser Asn Leu Val Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Ala Gln Asn 85 90 95 Leu Glu Leu Pro Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 110 Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 115 120 125 Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe 130 135 140 Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln 145 150 155 160 Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser 165 170 175 Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu 180 185 190 Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser 195 200 205 Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 210 215 <210> 4 <211> 449 <212> PRT <213> artificial sequence <220> <223> synthetic <400> 4 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Tyr Ser 20 25 30 Trp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Arg Ile Phe Pro Gly Asp Gly Asp Thr Asp Tyr Asn Gly Lys Phe 50 55 60 Lys Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asn Val Phe Asp Gly Tyr Trp Leu Val Tyr Trp Gly Gln Gly 100 105 110 Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe 115 120 125 Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu 130 135 140 Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp 145 150 155 160 Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu 165 170 175 Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser 180 185 190 Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro 195 200 205 Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys 210 215 220 Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro 225 230 235 240 Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser 245 250 255 Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp 260 265 270 Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn 275 280 285 Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val 290 295 300 Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu 305 310 315 320 Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys 325 330 335 Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr 340 345 350 Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr 355 360 365 Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu 370 375 380 Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu 385 390 395 400 Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys 405 410 415 Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu 420 425 430 Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 435 440 445 Light <210> 5 <211> 214 <212> PRT <213> artificial sequence <220> <223> synthetic <400> 5 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Gly Ala Ser Glu Asn Ile Tyr Gly Ala 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Gly Ala Thr Asn Leu Ala Asp Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Asn Val Leu Asn Thr Pro Leu 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys 210 <210> 6 <211> 448 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 6 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ile Phe Ser Asn Tyr 20 25 30 Trp Ile Gln Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Glu Ile Leu Pro Gly Ser Gly Ser Thr Glu Tyr Thr Glu Asn Phe 50 55 60 Lys Asp Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Tyr Phe Phe Gly Ser Ser Pro Asn Trp Tyr Phe Asp Val Trp 100 105 110 Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro 115 120 125 Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr 130 135 140 Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr 145 150 155 160 Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro 165 170 175 Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr 180 185 190 Val Pro Ser Ser Asn Phe Gly Thr Gln Thr Tyr Thr Cys Asn Val Asp 195 200 205 His Lys Pro Ser Asn Thr Lys Val Asp Lys Thr Val Glu Arg Lys Cys 210 215 220 Cys Val Glu Cys Pro Pro Cys Pro Ala Pro Pro Val Ala Gly Pro Ser 225 230 235 240 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 245 250 255 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro 260 265 270 Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 275 280 285 Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val 290 295 300 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 305 310 315 320 Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr 325 330 335 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 340 345 350 Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys 355 360 365 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 370 375 380 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 385 390 395 400 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser 405 410 415 Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 420 425 430 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys 435 440 445 <210> 7 <211> 214 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 7 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Val Asn Thr Ala 20 25 30 Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ser Ala Ser Phe Leu Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Arg Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro Pro 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys 210 <210> 8 <211> 450 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 8 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn Ile Lys Asp Thr 20 25 30 Tyr Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Arg Ile Tyr Pro Thr Asn Gly Tyr Thr Arg Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ser Arg Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 115 120 125 Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala 130 135 140 Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 145 150 155 160 Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 165 170 175 Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 180 185 190 Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys 195 200 205 Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp 210 215 220 Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly 225 230 235 240 Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile 245 250 255 Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu 260 265 270 Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 275 280 285 Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg 290 295 300 Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys 305 310 315 320 Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu 325 330 335 Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr 340 345 350 Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu 355 360 365 Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp 370 375 380 Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val 385 390 395 400 Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp 405 410 415 Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His 420 425 430 Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro 435 440 445 Gly Lys 450 <210> 9 <211> 412 <212> PRT <213> Homo sapiens <400> 9 Met Gln Pro Ser Ser Leu Leu Pro Leu Ala Leu Cys Leu Leu Ala Ala 1 5 10 15 Pro Ala Ser Ala Leu Val Arg Ile Pro Leu His Lys Phe Thr Ser Ile 20 25 30 Arg Arg Thr Met Ser Glu Val Gly Gly Ser Val Glu Asp Leu Ile Ala 35 40 45 Lys Gly Pro Val Ser Lys Tyr Ser Gln Ala Val Pro Ala Val Thr Glu 50 55 60 Gly Pro Ile Pro Glu Val Leu Lys Asn Tyr Met Asp Ala Gln Tyr Tyr 65 70 75 80 Gly Glu Ile Gly Ile Gly Thr Pro Pro Gln Cys Phe Thr Val Val Phe 85 90 95 Asp Thr Gly Ser Ser Asn Leu Trp Val Pro Ser Ile His Cys Lys Leu 100 105 110 Leu Asp Ile Ala Cys Trp Ile His His Lys Tyr Asn Ser Asp Lys Ser 115 120 125 Ser Thr Tyr Val Lys Asn Gly Thr Ser Phe Asp Ile His Tyr Gly Ser 130 135 140 Gly Ser Leu Ser Gly Tyr Leu Ser Gln Asp Thr Val Ser Val Pro Cys 145 150 155 160 Gln Ser Ala Ser Ser Ala Ser Ala Leu Gly Gly Val Lys Val Glu Arg 165 170 175 Gln Val Phe Gly Glu Ala Thr Lys Gln Pro Gly Ile Thr Phe Ile Ala 180 185 190 Ala Lys Phe Asp Gly Ile Leu Gly Met Ala Tyr Pro Arg Ile Ser Val 195 200 205 Asn Asn Val Leu Pro Val Phe Asp Asn Leu Met Gln Gln Lys Leu Val 210 215 220 Asp Gln Asn Ile Phe Ser Phe Tyr Leu Ser Arg Asp Pro Asp Ala Gln 225 230 235 240 Pro Gly Gly Glu Leu Met Leu Gly Gly Thr Asp Ser Lys Tyr Tyr Lys 245 250 255 Gly Ser Leu Ser Tyr Leu Asn Val Thr Arg Lys Ala Tyr Trp Gln Val 260 265 270 His Leu Asp Gln Val Glu Val Ala Ser Gly Leu Thr Leu Cys Lys Glu 275 280 285 Gly Cys Glu Ala Ile Val Asp Thr Gly Thr Ser Leu Met Val Gly Pro 290 295 300 Val Asp Glu Val Arg Glu Leu Gln Lys Ala Ile Gly Ala Val Pro Leu 305 310 315 320 Ile Gln Gly Glu Tyr Met Ile Pro Cys Glu Lys Val Ser Thr Leu Pro 325 330 335 Ala Ile Thr Leu Lys Leu Gly Gly Lys Gly Tyr Lys Leu Ser Pro Glu 340 345 350 Asp Tyr Thr Leu Lys Val Ser Gln Ala Gly Lys Thr Leu Cys Leu Ser 355 360 365 Gly Phe Met Gly Met Asp Ile Pro Pro Pro Ser Gly Pro Leu Trp Ile 370 375 380 Leu Gly Asp Val Phe Ile Gly Arg Tyr Tyr Thr Val Phe Asp Arg Asp 385 390 395 400 Asn Asn Arg Val Gly Phe Ala Glu Ala Ala Arg Leu 405 410 <210> 10 <211> 333 <212> PRT <213> Homo sapiens <400> 10 Met Asn Pro Thr Leu Ile Leu Ala Ala Phe Cys Leu Gly Ile Ala Ser 1 5 10 15 Ala Thr Leu Thr Phe Asp His Ser Leu Glu Ala Gln Trp Thr Lys Trp 20 25 30 Lys Ala Met His Asn Arg Leu Tyr Gly Met Asn Glu Glu Gly Trp Arg 35 40 45 Arg Ala Val Trp Glu Lys Asn Met Lys Met Ile Glu Leu His Asn Gln 50 55 60 Glu Tyr Arg Glu Gly Lys His Ser Phe Thr Met Ala Met Asn Ala Phe 65 70 75 80 Gly Asp Met Thr Ser Glu Glu Phe Arg Gln Val Met Asn Gly Phe Gln 85 90 95 Asn Arg Lys Pro Arg Lys Gly Lys Val Phe Gln Glu Pro Leu Phe Tyr 100 105 110 Glu Ala Pro Arg Ser Val Asp Trp Arg Glu Lys Gly Tyr Val Thr Pro 115 120 125 Val Lys Asn Gln Gly Gln Cys Gly Ser Cys Trp Ala Phe Ser Ala Thr 130 135 140 Gly Ala Leu Glu Gly Gln Met Phe Arg Lys Thr Gly Arg Leu Ile Ser 145 150 155 160 Leu Ser Glu Gln Asn Leu Val Asp Cys Ser Gly Pro Gln Gly Asn Glu 165 170 175 Gly Cys Asn Gly Gly Leu Met Asp Tyr Ala Phe Gln Tyr Val Gln Asp 180 185 190 Asn Gly Gly Leu Asp Ser Glu Glu Ser Tyr Pro Tyr Glu Ala Thr Glu 195 200 205 Glu Ser Cys Lys Tyr Asn Pro Lys Tyr Ser Val Ala Asn Asp Thr Gly 210 215 220 Phe Val Asp Ile Pro Lys Gln Glu Lys Ala Leu Met Lys Ala Val Ala 225 230 235 240 Thr Val Gly Pro Ile Ser Val Ala Ile Asp Ala Gly His Glu Ser Phe 245 250 255 Leu Phe Tyr Lys Glu Gly Ile Tyr Phe Glu Pro Asp Cys Ser Ser Glu 260 265 270 Asp Met Asp His Gly Val Leu Val Val Gly Tyr Gly Phe Glu Ser Thr 275 280 285 Glu Ser Asp Asn Asn Lys Tyr Trp Leu Val Lys Asn Ser Trp Gly Glu 290 295 300 Glu Trp Gly Met Gly Gly Tyr Val Lys Met Ala Lys Asp Arg Arg Asn 305 310 315 320 His Cys Gly Ile Ala Ser Ala Ala Ser Tyr Pro Thr Val 325 330 <210> 11 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 11 Tyr Cys Gln Gln Trp Thr Ser Asn Pro 1 5 <210> 12 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 12 Pro Lys Ser Cys Asp Lys Thr His Thr 1 5 <210> 13 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 13 Ala Ser Val Lys Met Ser Cys Lys Ala 1 5 <210> 14 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 14 Leu Leu Gly Gly Pro Ser Val Phe Leu 1 5 <210> 15 <211> 8 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 15 Leu Leu Gly Gly Pro Ser Val Phe 1 5 <210> 16 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 16 Lys Lys Ala Glu Pro Lys Ser Cys Asp 1 5 <210> 17 <211> 8 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 17 Lys Glu Pro Lys Ser Cys Asp Lys 1 5 <210> 18 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 18 Ala Glu Pro Lys Ser Cys Asp Lys Thr 1 5 <210> 19 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 19 Glu Pro Lys Ser Cys Asp Lys Thr His 1 5 <210> 20 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 20 Lys Ser Cys Asp Lys Thr His Thr Cys 1 5 <210> twenty one <211> 111 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> twenty one Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Val Asn Thr Ala 20 25 30 Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ser Ala Ser Phe Leu Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Arg Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro Pro 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala 100 105 110 <210> 22 <211> 214 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 22 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Val Asn Thr Ala 20 25 30 Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ser Ala Ser Phe Leu Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Arg Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro Pro 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys 210 <210> 23 <211> 240 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 23 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn Ile Lys Asp Thr 20 25 30 Tyr Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Arg Ile Tyr Pro Thr Asn Gly Tyr Thr Arg Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ser Arg Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 115 120 125 Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala 130 135 140 Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 145 150 155 160 Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 165 170 175 Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 180 185 190 Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys 195 200 205 Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp 210 215 220 Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly 225 230 235 240 <210> 24 <211> 8 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 24 Pro Ala Pro Glu Leu Leu Gly Gly 1 5 <210> 25 <211> 11 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 25 Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val 1 5 10 <210> 26 <211> 25 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 26 Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu 1 5 10 15 Pro Lys Ser Cys Asp Lys Thr His Thr 20 25 <210> 27 <211> 20 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 27 Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn 1 5 10 15 Arg Gly Glu Cys 20 <210> 28 <211> 11 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 28 Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys 1 5 10 <210> 29 <211> 10 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 29 Tyr Tyr Cys Ser Arg Trp Gly Gly Asp Phe 1 5 10 <210> 30 <211> 5 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 30 Arg Thr Val Ala Ala 1 5 <210> 31 <211> 14 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 31 Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 1 5 10 <210> 32 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 32 Ala Ala Thr Tyr Tyr Cys Gln Gln Trp 1 5 <210> 33 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 33 Lys Lys Ala Glu Pro Lys Ser Cys Asp 1 5 <210> 34 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 34 Lys Ala Glu Pro Lys Ser Cys Asp Lys 1 5 <210> 35 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 35 Ala Glu Pro Lys Ser Cys Asp Lys Thr 1 5 <210> 36 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 36 Glu Pro Lys Ser Cys Asp Lys Thr His 1 5 <210> 37 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 37 Lys Ser Cys Asp Lys Thr His Thr Cys 1 5 <210> 38 <211> 11 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 38 Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu 1 5 10 <210> 39 <211> 10 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 39 Pro Glu Leu Leu Gly Gly Pro Ser Val Phe 1 5 10 <210> 40 <211> 6 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 40 Ser Leu Arg Leu Ser Cys 1 5 <210> 41 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 41 Ser Arg Trp Gly Gly Asp Gly 1 5 <210> 42 <211> 6 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 42 Pro Gly Gly Ser Leu Arg 1 5 <210> 43 <211> 6 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 43 Ser Trp Arg Gly Gly Asp 1 5 <210> 44 <211> 5 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 44 Ser Arg Trp Gly Gly 1 5 <210> 45 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 45 Asn Val Asn His Lys Pro Ser 1 5 <210> 46 <211> 6 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 46 Ser Gly Gly Gly Leu Val 1 5 <210> 47 <211> 6 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 47 Gln Gly Thr Leu Val Thr 1 5 <210> 48 <211> 6 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 48 Gly Gly Leu Val Gln Pro 1 5 <210> 49 <211> 6 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 49 Leu Val Thr Val Ser Ser 1 5 <210> 50 <211> 5 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 50 Ser Arg Trp Gly Gly 1 5 <210> 51 <211> 6 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 51 Lys Lys Val Glu Pro Lys 1 5 <210> 52 <211> 6 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 52 Pro Ala Pro Ile Glu Lys 1 5 <210> 53 <211> 5 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 53 Ser Leu Ser Pro Gly 1 5 <210> 54 <211> 6 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 54 Val Ser Asn Lys Ala Leu 1 5 <210> 55 <211> 5 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 55 Ser Leu Ser Pro Gly 1 5 <210> 56 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 56 Arg Glu Glu Met Thr Lys Asn 1 5 <210> 57 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 57 His Tyr Thr Gln Lys Ser Leu 1 5 <210> 58 <211> 6 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 58 Lys Val Ser Asn Lys Ala 1 5 <210> 59 <211> 5 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 59 Ser Leu Ser Pro Gly 1 5 <210> 60 <211> 8 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 60 Glu Tyr Lys Cys Lys Val Ser Asn 1 5 <210> 61 <211> 5 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 61 Ser Leu Ser Pro Gly 1 5 <210> 62 <211> 5 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 62 Ser Arg Thr Pro Glu 1 5 <210> 63 <211> 6 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 63 His Glu Ala Leu His Asn 1 5 <210> 64 <211> 5 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 64 Gln Met Thr Gln Ser 1 5 <210> 65 <211> 6 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 65 Pro Ser Asp Glu Gln Leu 1 5 <210> 66 <211> 5 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 66 Val Thr Ile Thr Cys 1 5 <210> 67 <211> 5 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 67 Leu Ser Ser Pro Val 1 5 <210> 68 <211> 6 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 68 Asp Ile Gln Met Thr Gln 1 5 <210> 69 <211> 6 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 69 Lys Arg Thr Val Ala Ala 1 5 <210> 70 <211> 6 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 70 Ser Leu Arg Leu Ser Cys 1 5 <210> 71 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 71 Ser Ser Ala Ser Thr Lys Gly 1 5 <210> 72 <211> 5 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 72 Gly Asp Arg Val Thr 1 5 <210> 73 <211> 5 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 73 Gly Gln Gly Thr Lys 1 5 <210> 74 <211> 6 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 74 Ala Pro Ser Val Phe Ile 1 5 <210> 75 <211> 6 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 75 Gly Thr Leu Val Thr Val 1 5 <210> 76 <211> 6 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 76 Cys Asn Val Asn His Lys 1 5 <210> 77 <211> 6 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 77 Ser Lys Ser Thr Ser Gly 1 5 <210> 78 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 78 Asn Val Asn His Lys Pro Ser 1 5 <210> 79 <211> 5 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 79 Pro Ser Val Phe Ile 1 5 <210> 80 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 80 Val Tyr Ala Cys Glu Val Thr 1 5 <210> 81 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 81 Pro Ala Pro Glu Leu Leu Gly Gly Pro 1 5 <210> 82 <211> 13 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 82 Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu 1 5 10 <210> 83 <211> 8 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 83 Glu Leu Leu Gly Gly Pro Ser Val 1 5 <210> 84 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 84 Gly Gly Pro Ser Val Phe Leu Phe Pro 1 5 <210> 85 <211> 8 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 85 Glu Leu Leu Gly Gly Pro Ser Val 1 5 <210> 86 <211> 11 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 86 Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys 1 5 10 <210> 87 <211> 8 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 87 Pro Ala Pro Glu Leu Leu Gly Gly 1 5 <210> 88 <211> 11 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 88 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro 1 5 10 <210> 89 <211> 8 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 89 Pro Ala Pro Glu Leu Leu Gly Gly 1 5 <210> 90 <211> 13 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 90 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro 1 5 10 <210> 91 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 91 Ala Val Tyr Tyr Cys Ala Arg Asn Val 1 5 <210> 92 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 92 Phe Pro Leu Ala Pro Ser Ser Lys Ser 1 5 <210> 93 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 93 Leu Ala Pro Ser Ser Lys Ser Thr Ser 1 5 <210> 94 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 94 Ala Pro Ser Ser Lys Ser Thr Ser Gly 1 5 <210> 95 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 95 Pro Ser Ser Lys Ser Thr Ser Gly Gly 1 5 <210> 96 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 96 Cys Glu Val Thr His Gln Gly Leu Ser 1 5 <210> 97 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 97 Val Asp Lys Lys Val Glu Pro Lys Ser 1 5 <210> 98 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 98 Thr Lys Ser Phe Asn Arg Gly Glu Cys 1 5 <210> 99 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 99 Lys Lys Val Glu Pro Lys Ser Cys Asp 1 5 <210> 100 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 100 Lys Val Glu Pro Lys Ser Cys Asp Lys 1 5 <210> 101 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 101 Val Glu Pro Lys Ser Cys Asp Lys Thr 1 5 <210> 102 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 102 Glu Pro Lys Ser Cys Asp Lys Thr His 1 5 <210> 103 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 103 Lys Ser Cys Asp Lys Thr His Thr Cys 1 5 <210> 104 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 104 Glu Leu Leu Gly Gly Pro Ser Val Phe 1 5 <210> 105 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 105 Leu Leu Gly Gly Pro Ser Val Phe Leu 1 5 <210> 106 <211> 10 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 106 Glu Leu Leu Gly Gly Pro Ser Val Phe Leu 1 5 10 <210> 107 <211> 10 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 107 Pro Glu Leu Leu Gly Gly Pro Ser Val Phe 1 5 10 <210> 108 <211> 10 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 108 Leu Leu Gly Gly Pro Ser Val Phe Leu Phe 1 5 10 <210> 109 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 109 Tyr Cys Ala Arg Tyr Phe Phe Gly Ser 1 5 <210> 110 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 110 Cys Ala Arg Tyr Phe Phe Gly Ser Ser 1 5 <210> 111 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 111 Tyr Phe Phe Gly Ser Ser Pro Asn Trp 1 5 <210> 112 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 112 Val Tyr Tyr Cys Ala Arg Tyr Phe Phe 1 5 <210> 113 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 113 Tyr Cys Ala Arg Tyr Phe Phe Gly Ser 1 5 <210> 114 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 114 Cys Ala Arg Tyr Phe Phe Gly Ser Ser 1 5 <210> 115 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 115 Tyr Phe Phe Gly Ser Ser Pro Asn Trp 1 5 <210> 116 <211> 8 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 116 Pro Val Ala Gly Pro Ser Val Phe 1 5 <210> 117 <211> 8 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 117 Val Ala Gly Pro Ser Val Phe Leu 1 5 <210> 118 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 118 Pro Val Ala Gly Pro Ser Val Phe Leu 1 5 <210> 119 <211> 8 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 119 Val Ala Gly Pro Ser Val Phe Leu 1 5 <210> 120 <211> 8 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 120 Ala Gly Pro Ser Val Phe Leu Phe 1 5 <210> 121 <211> 13 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 121 Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 1 5 10 <210> 122 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 122 Pro Ser Ser Lys Ser Thr Ser Gly Gly 1 5 <210> 123 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 123 Ser Ser Leu Ser Ala Ser Val 1 5 <210> 124 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 124 His Lys Val Tyr Ala Cys Glu Val Thr 1 5 <210> 125 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 125 Trp Gly Gly Asp Gly Phe Tyr 1 5 <210> 126 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 126 Lys Lys Val Glu Pro Lys Ser Cys Asp 1 5 <210> 127 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 127 Phe Ile Phe Pro Pro Ser Asp Glu Gln 1 5 <210> 128 <211> 6 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 128 Phe Asn Arg Gly Glu Cys 1 5 <210> 129 <211> 10 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 129 Tyr Tyr Cys Ser Arg Trp Gly Gly Asp Phe 1 5 10 <210> 130 <211> 13 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 130 Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 1 5 10 <210> 131 <211> 8 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 131 Pro Ser Ser Lys Ser Thr Ser Gly 1 5 <210> 132 <211> 10 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 132 Tyr Tyr Cys Ser Arg Trp Gly Gly Asp Phe 1 5 10 <210> 133 <211> 4 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 133 Glu Val Gln Leu 1 <210> 134 <211> 5 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 134 Glu Pro Lys Ser Cys 1 5 <210> 135 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 135 Gly Leu Val Gln Pro Gly Gly 1 5 <210> 136 <211> 8 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 136 Ala Met Asp Tyr Trp Gly Gln Gly 1 5 <210> 137 <211> 8 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 137 Gly Thr Lys Val Glu Ile Lys Arg 1 5 <210> 138 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 138 Val Glu Ile Lys Arg Thr Val Ala Ala 1 5 <210> 139 <211> 10 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 139 Gly Gly Pro Ser Val Phe Leu Phe Pro Pro 1 5 10 <210> 140 <211> 8 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 140 Lys Gly Gln Pro Arg Glu Pro Gln 1 5 <210> 141 <211> 8 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 141 Val Ala Ala Pro Ser Val Phe Ile 1 5 <210> 142 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 142 Asp Tyr Trp Gly Gln Gly Thr Leu Val 1 5 <210> 143 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 143 Ser Val Phe Leu Phe Pro Pro Lys Pro 1 5 <210> 144 <211> 10 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 144 Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala 1 5 10 <210> 145 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 145 Glu Val Thr His Gln Gly Leu Ser Ser 1 5 <210> 146 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 146 Leu Ala Pro Ser Ser Lys Ser Thr Ser 1 5 <210> 147 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 147 Lys Lys Val Glu Pro Lys Ser Cys Asp 1 5 <210> 148 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 148 Pro Pro Thr Phe Gly Gln Gly 1 5 <210> 149 <211> 5 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 149 Asn Arg Gly Glu Cys 1 5 <210> 150 <211> 10 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 150 Lys Lys Val Glu Pro Lys Ser Cys Asp Lys 1 5 10 <210> 151 <211> 8 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 151 Pro Ala Pro Glu Leu Leu Gly Gly 1 5 <210> 152 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 152 Pro Ala Pro Glu Leu Leu Gly Gly Pro 1 5 <210> 153 <211> 4 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 153 Cys Glu Gly Arg 1 <210> 154 <211> 5 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 154 Cys Glu Gly Arg Asn 1 5 <210> 155 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 155 Cys Glu Gly Arg Asn Phe Ser 1 5 <210> 156 <211> 8 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 156 Cys Glu Gly Arg Asn Phe Ser Lys 1 5 <210> 157 <211> 10 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 157 Cys Glu Gly Arg Asn Phe Ser Lys Thr Val 1 5 10 <210> 158 <211> 11 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 158 Cys Glu Gly Arg Asn Phe Ser Lys Thr Val Pro 1 5 10 <210> 159 <211> 12 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 159 Cys Glu Gly Arg Asn Phe Ser Lys Thr Val Pro Ser 1 5 10 <210> 160 <211> 13 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 160 Cys Glu Gly Arg Asn Phe Ser Lys Thr Val Pro Ser Ser 1 5 10 <210> 161 <211> 14 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 161 Cys Glu Gly Arg Asn Phe Ser Lys Thr Val Pro Ser Ser Leu 1 5 10 <210> 162 <211> 16 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 162 Cys Glu Gly Arg Asn Phe Ser Lys Thr Val Pro Ser Ser Leu Gly Gln 1 5 10 15 <210> 163 <211> 17 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 163 Cys Glu Gly Arg Asn Phe Ser Lys Thr Val Pro Ser Ser Leu Gly Gln 1 5 10 15 His <210> 164 <211> 18 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 164 Cys Glu Gly Arg Asn Phe Ser Lys Thr Val Pro Ser Ser Leu Gly Gln 1 5 10 15 His Thr <210> 165 <211> 19 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 165 Cys Glu Gly Arg Asn Phe Ser Lys Thr Val Pro Ser Ser Leu Gly Gln 1 5 10 15 His Thr Val <210> 166 <211> 20 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 166 Cys Glu Gly Arg Asn Phe Ser Lys Thr Val Pro Ser Ser Leu Gly Gln 1 5 10 15 His Thr Val Glu 20 <210> 167 <211> 5 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 167 Cys Asp Lys Thr His 1 5 <210> 168 <211> 10 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 168 Cys Asp Lys Thr His Thr Cys Pro Pro Cys 1 5 10 <210> 169 <211> 12 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 169 Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala 1 5 10 <210> 170 <211> 13 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 170 Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro 1 5 10 <210> 171 <211> 15 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 171 Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu 1 5 10 15 <210> 172 <211> 18 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 172 Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu 1 5 10 15 Gly Gly <210> 173 <211> 5 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 173 Cys Lys Pro Glu Val 1 5 <210> 174 <211> 4 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 174 Cys Ser Lys Pro 1 <210> 175 <211> 5 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 175 Cys Ser Lys Pro Glu 1 5 <210> 176 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 176 Cys Ser Lys Pro Glu Val Lys Lys Asp 1 5 <210> 177 <211> 10 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 177 Cys Ser Lys Pro Glu Val Lys Lys Asp Val 1 5 10 <210> 178 <211> 11 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 178 Cys Ser Lys Pro Glu Val Lys Lys Asp Val Pro 1 5 10 <210> 179 <211> 12 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 179 Cys Ser Lys Pro Glu Val Lys Lys Asp Val Pro Thr 1 5 10 <210> 180 <211> 14 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 180 Cys Ser Lys Pro Glu Val Lys Lys Asp Val Pro Thr Asn Ser 1 5 10 <210> 181 <211> 16 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 181 Cys Ser Lys Pro Glu Val Lys Lys Asp Val Pro Thr Asn Ser Pro Lys 1 5 10 15 <210> 182 <211> 17 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 182 Cys Ser Lys Pro Glu Val Lys Lys Asp Val Pro Thr Asn Ser Pro Lys 1 5 10 15 His <210> 183 <211> 18 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 183 Cys Ser Lys Pro Glu Val Lys Lys Asp Val Pro Thr Asn Ser Pro Lys 1 5 10 15 His Asn
Claims
1. A method for analyzing the sequence of an antibody, comprising: a. The antibody is cleaved with cathepsin L, cathepsin D, or a combination of cathepsin L and cathepsin D to obtain one or more antibody fragments, wherein the antibody comprises a light chain and a heavy chain, the light chain comprising a light chain variable region (VL) and a light chain constant region (CL), the heavy chain comprising a heavy chain variable region (VH) and a heavy chain constant region (CH), and wherein the cathepsin L and / or cathepsin D cleaves the antibody between the VL and CL regions and / or between the VH and CH regions to produce VL antibody fragments and / or VH antibody fragments and CL antibody fragments and / or CH antibody fragments; b. Optionally, one or more of the antibody fragments are separated after the cleavage; and c. Perform mass spectrometry (MS) analysis on the one or more antibody fragments; The cutting process is performed at a pH value of 2 to 8, a temperature of 25°C to 50°C, and in the presence of no more than 50% organic solvent, including acetonitrile, methanol, ethanol, or isopropanol. Furthermore, the antibody is in its natural state.
2. The method according to claim 1, wherein the antibody is an IgG antibody.
3. The method according to claim 1, wherein the antibody is a human IgG1, IgG2, IgG2A, IgG2B or IgG4 antibody.
4. The method of claim 1, wherein the VL segment and / or VH segment are subjected to MS analysis.
5. The method of claim 1, wherein the method comprises cleaving the antibody with a combination of cathepsin L and cathepsin D.
6. The method of claim 1, wherein the method comprises simultaneously incubating the antibody with both cathepsin L and cathepsin D.
7. The method according to any one of claims 1 to 6, wherein cutting is performed to achieve at least 50% cutting between the VL region and the CL region and between the VH region and the CH region, and / or at or below the hinge to achieve at least 50% cutting.
8. The method according to any one of claims 1 to 6, wherein the cutting is performed at a ratio of cathepsin L and / or cathepsin D to antibody of 1:20 to 1:2000.
9. The method according to any one of claims 1 to 6, wherein the cutting is performed at a ratio of cathepsin L and / or cathepsin D to antibody of 1:20 to 1:
500.
10. The method according to any one of claims 1 to 6, wherein the cutting is performed at a ratio of cathepsin L and / or cathepsin D to antibody of 1:50 to 1:
500.
11. The method according to any one of claims 1 to 6, wherein the cutting is performed at a ratio of cathepsin L and / or cathepsin D to antibody of 1:100 to 1:
500.
12. The method according to any one of claims 1 to 6, wherein the cutting is performed at a ratio of cathepsin L and / or cathepsin D to antibody of 1:200 to 1:1000.
13. The method according to any one of claims 1 to 6, wherein the cutting is performed at a ratio of cathepsin L and / or cathepsin D to antibody of 1:200 to 1:2000.
14. The method according to any one of claims 1 to 6, wherein the cutting is performed at a ratio of cathepsin L and / or cathepsin D to antibody of 1:500 to 1:2000.
15. The method according to any one of claims 1 to 6, wherein the cutting is performed at a ratio of cathepsin L and / or cathepsin D to antibody of 1:1000 to 1:2000.
16. The method according to any one of claims 1 to 6, wherein the cutting is performed at a ratio of cathepsin L and / or cathepsin D to antibody of 1:20, 1:50, 1:100, 1:200, 1:300, 1:400, 1:500, or 1:1000.
17. The method according to any one of claims 1 to 6, wherein the antibody is an IgG antibody, and wherein the cleavage produces VL, VH, CL, CH1, CH2, CH3, CH2-CH3, bonded CL+CH1, F(ab') and F(ab')2 fragments.
18. The method according to any one of claims 1 to 6, wherein the pH is 3 to 5.
19. The method according to any one of claims 1 to 6, wherein the pH is 3.5 to 4.
5.
20. The method according to any one of claims 1 to 6, wherein the pH is 4.
21. The method according to any one of claims 1 to 6, wherein the organic solvent is present in an amount not exceeding 30%.
22. The method according to any one of claims 1 to 6, wherein the cutting is performed in the presence of 10% to 30% organic solvent.
23. The method according to any one of claims 1 to 6, wherein no more than 10% organic solvent is present.
24. The method according to any one of claims 1 to 6, wherein the temperature is between 37°C and 50°C.
25. A method for analyzing the sequence of an antibody, comprising: a. The antibody is cleaved with a combination of cathepsin L and cathepsin D to obtain one or more antibody fragments, said one or more antibody fragments comprising at least a light chain variable region (VL) fragment and / or a heavy chain variable region (VH) fragment. i. The antibodies therein are in a natural state; ii. The antibody comprises a light chain and a heavy chain, the light chain comprising a light chain variable region (VL) and a light chain constant region (CL), the heavy chain comprising a heavy chain variable region (VH) and a heavy chain constant region (CH), and wherein the cathepsin L and cathepsin D cleave the antibody between the VL and CL regions and / or between the VH and CH regions to produce VL antibody fragments and / or VH antibody fragments and CL antibody fragments and / or CH antibody fragments; and iii. The cutting is carried out at a temperature between 25°C and 50°C and at a pH between 3 and 5, and in the presence of no more than 30% organic solvent; b. Optionally, one or more of the antibody fragments are separated after the cleavage; and c. Perform mass spectrometry (MS) analysis on the one or more antibody fragments.
26. The method of claim 25, wherein the cutting is performed at a ratio of cathepsin L and / or cathepsin D to antibody of 1:20 to 1:2000.
27. The method of claim 25, wherein the cleavage is performed at a ratio of cathepsin L and / or cathepsin D to antibody of 1:20 to 1:
500.
28. The method of claim 25, wherein the cutting is performed at a ratio of cathepsin L and / or cathepsin D to antibody of 1:50 to 1:
500.
29. The method of claim 25, wherein the cutting is performed at a ratio of cathepsin L and / or cathepsin D to antibody of 1:100 to 1:
500.
30. The method of claim 25, wherein the cutting is performed at a ratio of cathepsin L and / or cathepsin D to antibody of 1:200 to 1:1000.
31. The method of claim 25, wherein the cutting is performed at a ratio of cathepsin L and / or cathepsin D to antibody of 1:200 to 1:2000.
32. The method of claim 25, wherein the cutting is performed at a ratio of cathepsin L and / or cathepsin D to antibody of 1:500 to 1:2000.
33. The method of claim 25, wherein the cleavage is performed at a ratio of cathepsin L and / or cathepsin D to antibody of 1:1000 to 1:2000.
34. The method of claim 25, wherein the cutting is performed at a ratio of cathepsin L and / or cathepsin D to antibody of 1:20, 1:50, 1:100, 1:200, 1:300, 1:400, 1:500, or 1:1000.
35. The method according to any one of claims 1 to 6 or 25 to 34, wherein, After cleavage, the one or more antibody fragments are subjected to one or more of the following: buffer exchange, chromatography, filtration, disulfide bond reduction, exposure to guanidine hydrochloride, or alkylation.
36. The method of claim 35, wherein the chromatography is liquid chromatography.
37. The method of claim 36, wherein the liquid chromatography is high performance liquid chromatography or capillary electrophoresis.
38. The method of claim 35, wherein the filtration is a molecular weight cutoff filtration.
39. The method according to any one of claims 1 to 6 or 25 to 34, wherein the one or more antibody fragments are separated by chromatography or filtration after cleavage.
40. The method of claim 35, wherein the one or more antibody fragments are separated by liquid chromatography.
41. The method according to any one of claims 1 to 6 or 25 to 34, wherein the mass spectrometry (MS) comprises LC-MS or LC-MS / MS.
42. The method according to any one of claims 1 to 6 or 25 to 34, wherein the one or more antibody fragments are not separated after cleavage.
43. The method according to any one of claims 1 to 6 or 25 to 34, wherein the mass spectrometry comprises direct infusion mass spectrometry (DIMS), static spray infusion mass spectrometry, or flow injection mass spectrometry.
44. The method according to any one of claims 1 to 6 or 25 to 34, wherein mass spectrometry data is used to determine the amino acid sequence of at least 10 amino acid segments of an antibody fragment.
45. The method of claim 44, wherein the amino acid sequence of at least 15 amino acid segments of an antibody fragment is determined.
46. The method of claim 44, wherein the amino acid sequence of at least 20 amino acid segments of an antibody fragment is determined.
47. The method according to any one of claims 1 to 6 or 25 to 34, wherein the amino acid sequence of at least one antibody CDR region is determined.
48. The method of claim 47, wherein the sequences of VH and / or VL CDR1, CDR2 and CDR3 are determined.
49. The method according to any one of claims 1 to 6 or 25 to 34, wherein the complete amino acid sequence of at least one antibody fragment is determined.
50. The method of claim 49, wherein the antibody fragment is a VH fragment and / or a VL fragment.
51. The method of claim 44, wherein the sequence is determined by top-down analysis.
52. The method of claim 51, wherein the sequence is further analyzed or confirmed by bottom-up analysis.
53. The method according to any one of claims 1 to 6 or 25 to 34, wherein the amino acid sequences of the antibody VH region and / or VL region are unknown.
54. The method according to any one of claims 1 to 6 or 25 to 34, wherein the amino acid sequence of the antibody is unknown.
55. The method according to any one of claims 1 to 6 or 25 to 34, comprising performing MS on the CL region and / or CH region of the antibody generated by the cleavage.
56. The method of claim 55, wherein the CL region and / or CH region are CL, CH1, CH2 and / or CH3 segments.
57. The method according to any one of claims 1 to 6 or 25 to 34, further comprising Edman degradation of at least one antibody fragment.
58. The method according to any one of claims 1 to 6 or 25 to 34, wherein the antibody remains in its natural state after the cleavage.
59. The method according to any one of claims 1 to 6 or 25 to 34, wherein the antibody is not treated with a denaturing agent or a disulfide reducing agent during or after the cleavage.
60. The method according to any one of claims 1 to 6 or 25 to 34, wherein the antibody retains its disulfide bonds during and after the cleavage.
61. The method according to any one of claims 1 to 6 or 25 to 34, comprising performing mass spectrometry (MS) analysis of one or more antibody fragments after the cleavage, wherein the antibody is still in its native state and has not been treated with a denaturing agent or a disulfide bond reducing agent prior to the MS analysis.
